预约演示
更新于：2026-04-03
Sotrovimab
更新于：2026-04-03
概要
基本信息
药物类型 单克隆抗体 |
别名 Sotrovimab(Genetical Recombination)、sotrovimab(r-INN)、GSK4182136 + [4] |
作用方式 抑制剂 |
作用机制 SARS-CoV-2 S protein抑制剂(冠状病毒刺突糖蛋白抑制剂) |
在研适应症 |
非在研适应症- |
最高研发阶段批准上市 |
首次获批日期 美国 (2021-05-26), |
最高研发阶段(中国)- |
特殊审评紧急使用授权 (美国) |
登录后查看时间轴
结构/序列
Sequence Code 569644962L
来源: *****
Sequence Code 616715821H
来源: *****
关联
28
项与 Sotrovimab 相关的临床试验CTIS2024-514071-17-00
Temporal kinetics of antibody and cellular response markers and relative impact of revaccination in patients recovered from COVID-19 after treatment with monoclonal antibodies
开始日期2022-09-13 |
申办/合作机构- |
NCT05305651
Prospective Cohort Study to Monitor the Emergence of SARS-CoV-2 Spike Viral Variants in Immunocompromised Non-hospitalized Patients Exposed to Sotrovimab in Great Britain: LUNAR Study
Sotrovimab binds to a conserved epitope on the severe acute respiratory syndrome coronavirus (SARS-CoV) and SARS-CoV-2 spike protein outside the receptor-binding motif and has been shown to reduce the risk of hospitalization and/or death when administered as early treatment in non-hospitalized patients that are at risk for progression to severe disease. Immunocompromised (IC) patients are prioritized to receive early treatment for COVID-19 as they are at high risk of disease progression, and because of their potential for prolonged viral shedding and the resulting increased risk of emergent viral mutations and potential onward community transmission.
This genomic surveillance study will aim to describe changes in the SARS-CoV-2 spike protein observed in IC participants receiving sotrovimab as standard of clinical care in sentinel sites at a national level to assess potential emergence of viral variants.
This genomic surveillance study will aim to describe changes in the SARS-CoV-2 spike protein observed in IC participants receiving sotrovimab as standard of clinical care in sentinel sites at a national level to assess potential emergence of viral variants.
开始日期2022-07-01 |
申办/合作机构 |
ISRCTN74418247
Prospective cohort study to monitor the emergence of SARS-CoV-2 spike viral variants in immunocompromised non-hospitalised patients exposed to sotrovimab in Great Britain: the LUNAR study
开始日期2022-06-21 |
申办/合作机构- |
100 项与 Sotrovimab 相关的临床结果
登录后查看更多信息
100 项与 Sotrovimab 相关的转化医学
登录后查看更多信息
100 项与 Sotrovimab 相关的专利（医药）
登录后查看更多信息
279
项与 Sotrovimab 相关的文献（医药）2026-02-01·JOURNAL OF THEORETICAL BIOLOGY
Antibody escape of SARS-CoV-2 variants of concern on receptor-binding domain: A computational approach
Article
作者: Tuong, Lam-Truong ; Tran, Van-Thanh ; Le, Minh-Tri ; Thai, Khac-Minh ; Nguyen, Dac-Nhan ; Tran, Viet-Hung ; Hoai Huynh, Phuong Nguyen ; Dang, Thoai-My ; Tran-Thi, Phuong-Uyen ; Nguyen, Quoc-Thai
The receptor-binding domain (RBD) of the spike protein is a critical functional component responsible for binding between the SARS-CoV-2 and the ACE2 receptor, as well as monoclonal antibodies. This research focuses on evaluating the ability of SARS-CoV-2 variants to reduce or evade neutralizing antibody responses. The RBD structures of wild type, Delta, and Omicron structures along with nine RBD-directed antibodies downloaded from the Protein Data Bank were subjected to docking simulations via the HADDOCK 2.4 server to calculate Haddock score, binding affinity (ΔG) and dissociation constant (Kd). The resulting complexes underwent molecular dynamics simulations for 100 ns using GROMACS, and the binding free energy was calculated using gmx_MMPBSA. The findings indicated that the L452R and T478K mutations in Delta, as well as the K417N, E484A, S477N, and Q493R mutations in Omicron, were predicted to be pivotal factors in the interaction with antibodies. Omicron exhibited a greater potential for immune evasion compared to Delta. Notably, the Sotrovimab antibody demonstrated robust interactions with both variants. Etesevimab exhibited strong binding with Delta but displayed a weaker connection with Omicron. Therefore, Sotrovimab and Etesevimab remain promising candidates for in vitro and in vivo testing against SARS-CoV-2 variants.
2026-01-02·Infectious Diseases
Activity of sotrovimab in early clearance of SARS CoV-2 infection in severe immunocompromised patients: results of a prospective, monocentric study
Article
作者: Sardanelli, Alessia ; Gentile, Ivan ; Annunziata, Mario ; Cattaneo, Letizia ; Trucillo, Emilia ; Pietroluongo, Daria ; Foggia, Maria ; Grimaldi, Francesco ; D’Agostino, Alessia ; di Bernardo, Salvatore ; Buonomo, Antonio Riccardo ; Viceconte, Giulio
BACKGROUND:
The combination of antivirals and monoclonal antibodies (mAbs) in the first phase of COVID-19 has demonstrated to reduce time to viral clearance, but the superiority of combination compared to antiviral monotherapy is still debated.
RESEARCH DESIGN AND METHODS:
In an observational, prospective study, we enrolled immunocompromised outpatients with mild-to-moderate COVID-19 treated with one antiviral monotherapy within 7 days from symptoms onset, with or without sotrovimab from January 1, 2024 to October 31, 2024, and we compared them to an identical cohort of patients treated with a combination of one antiviral and sotrovimab, from May 1, 2023 to December 30, 2023. 1st of May 2023 and 31st of October 2024. Sotrovimab administered until the end of October 2023 was considered to be presumably effective against the circulating viral variants, based on virological reports.
RESULTS:
We enrolled considered 98 patients treated with nirmatrelvir/ritonavir or remdesivir. Sotrovimab was co-administered in 50/98 cases. All the patients cleared SARS-CoV-2 infection within a median of 17 (IQR 10-22) days. At the multivariate Cox regression analysis, therapy administration within 3 days from symptoms' onset (aHR 1.68; p = 0.031) and presumed sotrovimab effectiveness (aHR 1.75; p = 0.02) were found to be independent factors associated with for shorter time to viral clearance.
CONCLUSIONS:
The timing of administration of early antiviral therapy is crucial to reduce SARS-CoV-2 infection duration in immunocompromised patients and the combination with a mAb is associated with earlier viral clearance, as long asmAb is chosen among those effective against circulating variants.
2026-01-01·BIOPHYSICAL JOURNAL
An integrated multiscale computational framework deciphers SARS-CoV-2 resistance to sotrovimab
Article
作者: Kar, Rajiv K ; Tripathi, Timir ; Sharma, Akshit ; Padhi, Aditya K ; Maurya, Shweata ; Kumar, Shivank
The emergence of resistance mutations in the SARS-CoV-2 spike (S) protein presents a challenge for monoclonal antibody treatments like sotrovimab. Understanding the structural, dynamic, and molecular features of these mutations is essential for therapeutic advancements. However, the intricate landscape of potential mutations and critical residues conferring resistance to mAbs like sotrovimab remains elusive. This study introduces an integrated framework that combines interface protein design, machine learning, hybrid quantum mechanics/molecular mechanics methodologies, all-atom and coarse-grained molecular dynamics simulations, and correlation analysis. Beginning with the interface-based design and analysis, this framework elucidates the interaction between sotrovimab and the S-protein, identifying pivotal residues and plausible resistance mutations. Machine learning algorithms then facilitate the identification of potential resistance mutations using structural-sequence-binding affinity-energetics features. The hybrid quantum mechanics/molecular mechanics approach subsequently evaluates the role of mutational residues as quantum regions, assessing their impact on stabilizing the macromolecular complex. To gain a deeper understanding of the dynamic behavior of these mutations, multiscale simulations comprising all-atom and coarse-grained molecular dynamics simulations were performed, revealing their structural, biophysical and energetic impacts. These simulations complemented the static predictions, capturing the conformational dynamics and stability of the mutants in presence of glycan in the S-protein. The accuracy of the predictions is validated by correlating identified resistance mutations with clinical-sequencing data and empirical evidence from sotrovimab-treated patients. Notably, two residues, E340 at the S-protein-sotrovimab interface and Y508 distal from it, and their designs, align with clinically observed resistance mutations. Furthermore, machine learning approaches predict novel S-protein sequences with enhanced/reduced affinity for sotrovimab, validated structurally using AlphaFold. This integrated framework showcases its effectiveness in identifying potential resistance mutations, corroborated with clinical insights and offering a multidimensional strategy for decoding resistance mutations in SARS-CoV-2. Its translational relevance extends to understanding resistance mechanisms and designing novel antibody therapeutics in other systems.
224
项与 Sotrovimab 相关的新闻（医药）2026-04-02
THE LANCET Infectious Diseases. Volume 26Number 1
柳叶刀传染病学 26卷 1期
https://www.thelancet.com/journals/laninf/issue/current
EDITORIAL(社论)
1
Urgent need for infection prevention and control in prisons
监狱中感染预防和控制的迫切需求
The Lancet Infectious Diseases
The Lancet Infectious Diseases Vol 26(1):p1
COMMENT（述评）
2
Now is the time to integrate serology into routine infectious disease surveillance
现在是时候将血清学纳入常规传染病监测了
Simon Cauchemez
The Lancet Infectious Diseases Vol 26(1):p2
3
Reassessing sotrovimab's role in COVID-19: insights and implications
重新评估索托维单抗在新冠肺炎治疗中的作用：见解与启示
Daniele Focosi,Fabrizio Maggi
The Lancet Infectious Diseases Vol 26(1):p3
4
Shaping opportunities for future clinical trials in tuberculosis
为未来结核病临床试验创造机会
Ivan Noreña,Beno Mbeya,Joanitah Nalunjogi,Ombeni Chimbe,Norbert Heinrich
The Lancet Infectious Diseases Vol 26(1):p5
5
Diversifying antimalarial treatment for uncomplicated Plasmodium falciparum malaria in Uganda
乌干达针对无并发症恶性疟原虫疟疾的抗疟治疗多样化
Arjen M Dondorp
The Lancet Infectious Diseases Vol 26(1):p6
6
A safe start for PfSPZ Vaccine, but efficacy in children remains elusive
PfSPZ疫苗安全起步，但在儿童中的疗效仍难以捉摸
Nicholas Aderinto,Temitomi Jane Oyedele
The Lancet Infectious Diseases Vol 26(1):p8
7
Rifasutenizol-based triple therapy for Helicobacter pylori infection
以利法苏替尼唑为基础的三联疗法治疗幽门螺杆菌感染
Jinnan Chen,Hong Lu
The Lancet Infectious Diseases Vol 26(1):p9
8
The smallest faith
最渺小的信念
Steven A Pergam
The Lancet Infectious Diseases Vol 26(1):p11
9
Negative results in long COVID clinical trials: choosing outcome measures for a heterogeneous disease
新冠肺炎长期症状临床试验的阴性结果：为异质性疾病选择预后指标
Lara Goxhaj,Lisa McCorkell,Femke van Rhijn-Brouwer,Letícia Soares,Julia Moore Vogel,Chloé de Canson
The Lancet Infectious Diseases Vol 26(1):p13
10
Strengthening global preparedness and response to arboviral disease threats: a call to action
加强全球应对虫媒病毒疾病威胁的准备和响应：行动呼吁
WHO Global Arbovirus Initiative Technical Advisory Group
世界卫生组织全球虫媒病毒倡议技术咨询小组
The Lancet Infectious Diseases Vol 26(1):p15
11
Introducing our cover artist for 2026: Daria Lada
介绍我们2026年的封面艺术家：达里亚·拉达
Marco De Ambrogi
The Lancet Infectious Diseases Vol 26(1):p17
Correspondence（读者来信）
12
Epidemiological and virological update on the emerging SARS-CoV-2 variant BA.3.2
新兴新冠病毒变异株BA.3.2的流行病学和病毒学最新情况
Lu Zhang,Nianzhen Chen,Amy Eichmann,Inga Nehlmeier,Anna-Sophie Moldenhauer,Metodi V Stankov,Christine Happle,Alexandra Dopfer-Jablonka,Georg M N Behrens,Markus Hoffmann,Stefan Pöhlmann
The Lancet Infectious Diseases Vol 26(1):e1
13
Effects of LP.8.1-adapted mRNA vaccination on SARS-CoV-2 variant neutralisation
Christine Happle,Markus Hoffmann,Metodi V Stankov,Inga Nehlmeier,Amy Eichmann,Torsten LP.8.1适应性mRNA疫苗接种对新冠病毒变异株中和作用的影响
Witte,Luis Manthey,Stefan Pöhlmann,Alexandra Dopfer-Jablonka,Georg M N Behrens
The Lancet Infectious Diseases Vol 26(1):e3
14
Artificial intelligence and spillover prediction: aligning innovation with empirical reality in One Health surveillance
人工智能与溢出预测：在“同一健康”监测中使创新与经验现实保持一致
Nader Ebrahimi,Amir Ghaemi
The Lancet Infectious Diseases Vol 26(1):e6
15
Artificial intelligence and spillover prediction: aligning innovation with empirical reality in One Health surveillance – Authors' reply
人工智能与溢出预测：在“同一健康”监测中使创新与经验现实保持一致——作者回复
Frank Aarestrup,Marion Koopmans
The Lancet Infectious Diseases Vol 26(1):e7
16
Time to tackle vaccine–HLA associations with artificial intelligence
是时候用人工智能解决疫苗-人类白细胞抗原关联问题了
Alexander J Mentzer,George Davey Smith,Teresa Lambe,Julian C Knight,Mary Carrington
The Lancet Infectious Diseases Vol 26(1):e8
Corrections（更正）
17
Correction to Lancet Infect Dis 2025; published online Oct 29.
《柳叶刀-传染病》2025年更正；在线发表于10月29日
https://doi.org/10.1016/S1473-3099(25)00466-9
The Lancet Infectious Diseases Vol 26(1):e9
18
Correction to Lancet Infect Dis 2025; published online Oct 27.
《柳叶刀-传染病》2025年更正；在线发表于10月27日
https://doi.org/10.1016/S1473-3099(25)00546-8
The Lancet Infectious Diseases Vol 26(1):e9
19
Correction to Lancet Infect Dis 2025; 25: 1084–96
《柳叶刀-传染病》2025年更正；25卷：1084-1096页
The Lancet Infectious Diseases Vol 26(1):e9
20
Correction to Lancet Infect Dis 2025; published online Nov 10.
《柳叶刀-传染病》2025年更正；在线发表于11月10日
https://doi.org/10.1016/S1473-3099(25)00550-X
The Lancet Infectious Diseases Vol 26(1):e9
Newsdesk（新闻台）
21
Highlights of IDWeek 2025
2025年IDWeek亮点
Phoebe Hall
The Lancet Infectious Diseases Vol 26(1):e10
22
WHO publishes update on global antibiotic resistance
世界卫生组织发布全球抗生素耐药性最新情况
Timothy Jesudason
The Lancet Infectious Diseases Vol 26(1):e11
23
European Commission to fund new medicines for dengue
欧盟委员会资助登革热新药研发
Sanjeet Bagcchi
The Lancet Infectious Diseases Vol 26(1):e12
24
Second report from the UK Covid-19 Inquiry
英国新冠肺炎调查第二次报告
Talha Burki
The Lancet Infectious Diseases Vol 26(1):e13
25
Infectious disease surveillance update
传染病监测最新情况
Cahal McQuillan
The Lancet Infectious Diseases Vol 26(1):e14
26
Research in brief
研究简讯
Priya Venkatesan
The Lancet Infectious Diseases Vol 26(1):e15
Obituary（讣告）
27
Jean Louis Abdourahim Ndiaye
让·路易斯·阿卜杜拉希姆·恩迪亚耶
Sanjeet Bagcchi
The Lancet Infectious Diseases Vol 26(1):p19
Profile（人物介绍）
28
Fortunate Machingura—tackling climate change and disease
福图纳特·马辛古拉——应对气候变化与疾病
Tony Kirby
The Lancet Infectious Diseases Vol 26(1):p20
Media Watch（媒体观察）
Book（书籍）
29
The social and political drivers behind pandemics
大流行背后的社会和政治驱动因素
Emma Louise Fabiani
The Lancet Infectious Diseases Vol 26(1):p21
Articles（论著）
30
Dynamics of endemic virus re-emergence in children in the USA following the COVID-19 pandemic (2022–23): a prospective, multicentre, longitudinal, immunoepidemiological surveillance study
新冠肺炎疫情后美国儿童地方性病毒重新出现的动态（2022-23年）：一项前瞻性、多中心、纵向、免疫流行病学监测研究
Hai Nguyen-Tran,Sang Woo Park,Matthew R Vogt,Perdita Permaul,Alicen B Spaulding,Michelle L Hernandez,Jennifer A Bohl,Sucheta Godbole,Tracy J Ruckwardt,Peter W Krug,Daniel L Moss,Alexandrine Derrien-Colemyn,Ananda Chowdhury,Gabrielle Dziubla,Lu Wang,Mike Castro,Sandeep R Narpala,Elizabeth R Longtine,Amy R Henry,Teri-T B Ngo,Leonid Dzantiev,George B Sigal,C Jessica Metcalf,David W Kimberlin,Samuel R Dominguez,Abraham Mittelman,Adrian B McDermott,Leonid A Serebryannyy,Bryan Grenfell,Kevin Messacar,Daniel C Douek
The Lancet Infectious Diseases Vol 26(1):p22
31
Sotrovimab versus usual care in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
索托维单抗与常规治疗对住院新冠肺炎患者的疗效对比（RECOVERY）：一项随机、对照、开放标签、平台试验
RECOVERY Collaborative Group
RECOVERY协作组
The Lancet Infectious Diseases Vol 26(1):p34
32
A 3-month clofazimine–rifapentine-containing regimen for drug-susceptible tuberculosis versus standard of care (Clo-Fast): a randomised, open-label, phase 2c clinical trial
含氯法齐明-利福喷丁的3个月方案与标准治疗方案治疗药物敏感性结核病的对比（Clo-Fast）：一项随机、开放标签、2c期临床试验
John Z Metcalfe,Isabelle R Weir,Kimberly K Scarsi,Alberto Mendoza-Ticona,Samuel Pierre,Luke Hall,Jorge Leon-Cruz,Elin M Svensson,Simon E Koele,Wadzanai Samaneka,Cecilia Kanyama,Maxwell Yohane,Neetal Nevrekar,Busisiwe Ntsalaze,Jean Bernard Marc,Melanie Goth,Gary Maartens,Richard Chaissonon behalf of the ACTG A5362 study team
The Lancet Infectious Diseases Vol 26(1):p46
33
Global policy responses to antimicrobial resistance, 2021–22: a systematic governance analysis of 161 countries and territories
2021-22年全球应对抗菌药物耐药性的政策反应：对161个国家和地区进行的系统性治理分析
Jay Patel,Sahar Saeedi Moghaddam,Sruthi Ranganathan,Neil Vezeau,Emily O'Neill,Anne Harant,Michael Stolpe,Lothar H Wieler,Tim Eckmanns,Devi Sridhar
The Lancet Infectious Diseases Vol 26(1):p55
34
Efficacies of artemether–lumefantrine, artesunate–amodiaquine, dihydroartemisinin–piperaquine, and artesunate–pyronaridine for the treatment of uncomplicated Plasmodium falciparum malaria in children aged 6 months to 10 years in Uganda: a randomised, open-label, phase 4 clinical trial
乌干达6个月至10岁儿童使用蒿甲醚-本芴醇、青蒿琥酯-阿莫地喹、双氢青蒿素-哌喹和青蒿琥酯-吡喃隆治疗无并发症恶性疟原虫疟疾的疗效：一项随机、开放标签、4期临床试验
Moses R Kamya,Joaniter I Nankabirwa,Chris Ebong,Victor Asua,Moses Kiggundu,Stephen Orena,Martin Okitwi,Stephen Tukwasibwe,Bosco Agaba,Daniel Kyabayinze,Jimmy Opigo,Damian Rutazana,Benjamin Binagwa,Edward Mugwanya,Shakira Babirye,Gloria Sebikaari,Patrick M Condo,Grace Appiah,Sam L Nsobya,Melissa D Conrad,Philip J Rosenthal,Leah F Moriarty,Adoke Yeka
The Lancet Infectious Diseases Vol 26(1):p67
35
Safety, tolerability, and protective efficacy of a radiation-attenuated, whole sporozoite malaria vaccine in children in Gabon: a randomised, double-blind, placebo-controlled, phase 2 trial
加蓬儿童使用辐射减毒全孢子虫疟疾疫苗的安全性、耐受性和保护效力：一项随机、双盲、安慰剂对照、2期试验
Selidji T Agnandji,Jeroen Bok,Ayodele Alabi,Anita L Kabwende,Armel Mbouna,Juste Bie,Eleonne Moukiti,Albert Lalremruata,Meral Esen,Andrea Kreidenweiss,Natasha KC,B Kim Lee Sim,Thomas L Richie,L W Preston Church,Matthew B B McCall,Stephen L Hoffman,Peter G Kremsner,Benjamin Mordmüller
The Lancet Infectious Diseases Vol 26(1):p79
36
Effectiveness of the TAK-003 dengue vaccine in adolescents during the 2024 outbreak in São Paulo, Brazil: a test-negative, case–control study
TAK-003登革热疫苗在2024年圣保罗暴发期间对青少年的有效性：一项测试阴性病例对照研究
Otavio T Ranzani,Felippe Lazar Neto,Lisany Krug Mareto,Thiago Sanches Brumatti,Roberto Dias de Oliveira,Patricia Vieira da Silva,Edinéia Ribeiro dos Santos,Tatiana Lang D' Agostini,Regiane A Cardoso De Paula,Natalie E Dean,Albert I Ko,Derek A T Cummings,Jason R Andrews,Matt D T Hitchings,Julio Croda
The Lancet Infectious Diseases Vol 26(1):p91
37
Rifasutenizol-based triple therapy versus bismuth plus clarithromycin-based triple therapy for first-line treatment of Helicobacter pylori infection in China (EVEREST-HP): a phase 3, multicentre, randomised, triple-dummy, double-blind, controlled, non-inferiority trial
以利法苏替尼唑为基础的三联疗法与铋剂加克拉霉素为基础的三联疗法作为中国幽门螺杆菌感染一线治疗的对比（EVEREST-HP）：一项3期、多中心、随机、三模拟、双盲、对照、非劣效性试验
Zhiqiang Song,Liya Zhou,Weihong Wang,Cheng Lan,Tongyu Tang,Jun Xie,Huizhen Fan,Xuehong Wang,Xiuli Zuo,Yin Zhu,Chengxia Liu,Yongsong Gu,Huang Feng,Xiang Gao,Qing Zhang,Hong Zhang,Jing Chen,Guozhu Geng,Zhenkun Maon behalf of the EVEREST-HP Study Group
The Lancet Infectious Diseases Vol 26(1):p101
Series（专题研讨会）
38
Prevention and Management of Infections in People who are Immunocompromised
免疫功能低下人群感染的预防和治疗
Innovation in active and passive immunisation of people who are immunocompromised: a call to action
免疫功能低下人群主动和被动免疫接种的创新：行动呼吁
Joshua A Hill,Jim Boonyaratanakornkit,Malgorzata Mikulska,Benjamin W Teh,William O Hahn,Ghady Haidar,Catherine Liu,Deepali Kumar,Michael G Ison,Natasha Halasa
The Lancet Infectious Diseases Vol 26(1):e16
39
Prevention and Management of Infections in People who are Immunocompromised
免疫功能低下人群感染的预防和治疗
Tackling antimicrobial resistance in people who are immunocompromised: leveraging diagnostic and antimicrobial stewardship
应对免疫功能低下人群的抗菌药物耐药性：利用诊断和抗菌药物管理
Catherine Liu,Emily A Rosen,Erica J Stohs,Hannah Imlay,Masayuki Nigo,Lee S Gottesdiener,Miranda So,Frank Tverdek,Sanjeet Dadwal,Carlota Gudiol,Michael J Satlin,Susan K Seo,Jason A Trubiano,Ritu Banerjee,Kimberly E Hanson,Lilian M Abbo
The Lancet Infectious Diseases Vol 26(1):e30
Review（综述）
40
Unveiling the incidences and trends of alveolar echinococcosis in Europe: a systematic review from the KNOW-PATH project
揭示欧洲肺泡棘球蚴病的发病率和趋势：来自KNOW-PATH项目的系统综述
Adriano Casulli,Bernadette Abela,Daniele Petrone,Barbara Šoba,Balázs Dezsényi,Jacek Karamon,Laurence Millon,Urmas Saarma,Daniela Antolová,François Chappuis,Severin Gloor,Marcel Stoeckle,Beat Müllhaupt,Relja Beck,Heimo Lagler,Felix Lötsch,Herbert Auer,Marie-Pierre Hayette,Libuše Kolářová,Sniedze Laivacuma,Mindaugas Šarkūnas,Vitalijus Sokolovas,Audronė Marcinkutė,Karin Troell,Ansgar Deibel,Pikka Jokelainen,Małgorzata Sulima,Dagny Krankowska,Stillhard Roman,Gaëtan-Romain Joliat,Nermin Halkic,Solange Bresson-Hadni,Joanna Halina Bednarek,Andrzej Załęski,Małgorzata Paul,Sheraz Yaqub,Mogens Jensenius,Joke van der Giessen,Laura Nabarro,Peter Chiodini,Florent Demonmerot,Jenny Knapp,Beate Grüner,Peter Kern,Lynn Peters,Federica Santolamazza,Azzurra Santoro
The Lancet Infectious Diseases Vol 26(1):e49
Personal View（个人观点）
41
Azithromycin mass drug administration: balancing survival benefits and risks in children
阿奇霉素大规模药物给药：平衡儿童生存益处与风险
Nubwa Medugu,Ian C Michelow,Claudette Poole,Stephen K Obaro
The Lancet Infectious Diseases Vol 26(1):e62
Clinical Picture（临床影像）
42
Unexpected finding in a 17-year-old female undergoing screening colonoscopy
17岁女性接受筛查结肠镜检查时的意外发现
Ziheng Calvin Xu,Ethan Tan,Mayur Garg
The Lancet Infectious Diseases Vol 26(1):e75
THE LANCET Infectious Diseases. Volume 26Number 2
柳叶刀传染病学 26卷 2期
https://www.thelancet.com/journals/laninf/issue/current
EDITORIAL(社论)
1
Call for letters
征稿启事
The Lancet Infectious Diseases
The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：p111
Comment（述评）
2
Long COVID is here to stay—even in children
长期新冠症状将持续存在——即使在儿童中亦是如此
Danilo Buonsenso
The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：p112
3
Beyond ritonavir-boosted nirmatrelvir: the case for ensitrelvir in COVID-19 treatment
利托那韦强化版奈玛特韦之外的选择：恩赛特韦在新冠肺炎治疗中的应用
Ming Hong Choi,Ivan Fan Ngai Hung
The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：p113
4
A new monoclonal in the arMAMentarium against malaria
抗疟“武器库”中的新型单克隆抗体
Freia-Raphaella Lorenz,Matthew B B McCall
The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：p115
5
Household transmission of mpox in Africa: limited in adults but more prevalent in children
非洲猴痘家庭传播情况：在成人中传播有限，但在儿童中更为普遍
Oriol Mitjà,Michael Marks
The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：p117
6
The lasting lessons of mpox: infection, vaccination, and immune memory
猴痘带来的持久教训：感染、疫苗接种和免疫记忆
Raianna Fantin,Camila H Coelho
The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：p118
7
Xpert-Ultra for diagnosing asymptomatic tuberculosis
Xpert-Ultra用于诊断无症状结核病
Xia Yu,Hairong Huang
The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：p120
8
The genomic surveillance gap: averting the antimicrobial resistance pandemic requires global equity and action
基因组监测的差距：避免抗菌药物耐药性大流行需要全球公平与行动
David M Aanensen,Iruka N Okeke,Pilar Donado-Godoy,Beverly Egyir,Ravikumar K Lingegowda,Sonia Siaon behalf of the NIHR Global Health Research Unit on Genomic Surveillance of AMR
The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：p122
Correspondence（读者来信）
9
Spillover in dengue trials
登革热试验中的溢出效应
Thomas A Smith,Samuel I Watson
The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：e77
10
Spillover in dengue trials – Author's reply
登革热试验中的溢出效应——作者回复
Fernando Abad-Franch
The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：e78
11
Updating the traditional voriconazole trough concentration range
传统的伏立康唑谷浓度范围更新
Rongqiang Liao,Xiaoyuan Zheng
The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：e79
12
Updating the traditional voriconazole trough concentration range – Authors' reply
传统的伏立康唑谷浓度范围更新——作者回复
Inderpaul Singh Sehgal,Ritesh Agarwal,Valliappan Muthu
The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：e80
13
Clinical course and neurological profile of Kyasanur Forest disease
基萨努尔森林病的临床病程和神经特征
Nitin Gupta,Tirlangi Praveen Kumar
The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：e82
Corrections（更正）
14
Correction to Lancet Infect Dis 2025; published online Oct 10. https://doi.org/10.1016/S1473-3099(25)00482-7
对《柳叶刀-传染病》2025年发表内容的更正；10月10日在线发表。https://doi.org/10.1016/S1473-3099(25)00482-7
The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：e83
15
Correction to Lancet Infect Dis 2025; published online Dec 1. https://doi.org/10.1016/S1473-3099(25)00681-4
对《柳叶刀-传染病》2025年发表内容的更正；12月1日在线发表。https://doi.org/10.1016/S1473-3099(25)00681-4
The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：e83
Newsdesk（新闻台）
16
Promising early data for sorfequiline
索氟维林早期数据令人鼓舞
Ed Holt
The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：e84
17
Highlights from ASTMH 2025
2025年美国热带医学与卫生学会年会亮点
Marco De Ambrogi
The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：e85
18
Brazil approves domestic single-shot dengue vaccine
巴西批准国产单剂登革热疫苗
Marcia Triunfol
The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：e86
19
CDC cuts to childhood vaccine recommendations
美国疾控中心削减儿童疫苗接种建议
Priya Venkatesan
The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：e87
20
WHO launches unified plan for coronaviruses
世界卫生组织启动冠状病毒统一计划
Talha Burki
The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：e88
21
Infectious disease surveillance update
传染病监测更新
Cahal McQuillan
The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：e89
22
Research in brief
研究简讯
Priya Venkatesan
The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：e90
Obituary（讣告）
23
Walter Dowdle
沃尔特·道德尔
Sanjeet Bagcchi
The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：p124
Profile（人物简介）
24
Katie Anders—improving global dengue control
凯蒂·安德斯——改善全球登革热防控
Tony Kirby
The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：p125
Media Watch（媒体观察）
Film（电影）
25
Eliminating Guinea worm
根除麦地那龙线虫
Sanjeet Bagcchi
The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：p126
Articles（论著）
26
Long COVID associated with SARS-CoV-2 reinfection among children and adolescents in the omicron era (RECOVER-EHR): a retrospective cohort study
奥密克戎时代儿童与青少年长期新冠症状与SARS-CoV-2再感染的关联（RECOVER-EHR）：一项回顾性队列研究
Bingyu Zhang,Qiong Wu,Ravi Jhaveri,Ting Zhou,Michael J Becich,Yuriy Bisyuk,Frank Blanceró,Elizabeth A Chrischilles,Cynthia H Chuang,Lindsay G Cowell,Daniel Fort,Carol R Horowitz,Susan Kim,Nathalia Ladino,David M Liebovitz,Mei Liu,Abu S M Mosa,Hayden T Schwenk,Srinivasan Suresh,Bradley W Taylor,David A Williams,Jeffrey S Morris,Christopher B Forrest,Yong Chenon behalf of the RECOVER Consortium
The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：p127
27
Antiviral efficacy of oral ensitrelvir versus oral ritonavir-boosted nirmatrelvir in COVID-19 (PLATCOV): an open-label, phase 2, randomised, controlled, adaptive trial
口服恩赛特韦与口服利托那韦强化版奈玛特韦在新冠肺炎治疗中的抗病毒疗效（PLATCOV）：一项开放标签、2期、随机、对照、适应性试验
William H K Schilling,Podjanee Jittamala,Phrutsamon Wongnak,James A Watson,Simon Boyd,Viravarn Luvira,Tanaya Siripoon,Thundon Ngamprasertchai,Elizabeth M Batty,Ellen Beer,Shivani Singh,Tanatchakorn Asawasriworanan,Timothy Seers,Koukeo Phommasone,Terry John Evans,Varaporn Kruabkontho,Thatsanun Ngernseng,Jaruwan Tubprasert,Mohammad Yazid Abdad,Wanassanan Madmanee,Jindarat Kouhathong,Kanokon Suwannasin,Watcharee Pagornrat,Tianrat Piteekan,Borimas Hanboonkunupakarn,Kittiyod Poovorawan,Manus Potaporn,Attasit Srisubat,Bootsakorn Loharjun,Kesinee Chotivanich,Mallika Imwong,Sasithon Pukrittayakamee,Arjen M Dondorp,Nicholas P J Day,Watcharapong Piyaphanee,Weerapong Phumratanaprapin,Nicholas J Whiteon behalf of the PLATCOV Collaborative Group
The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：p139
28
Cefiderocol versus standard therapy for hospital-acquired and health-care-associated Gram-negative bacterial bloodstream infection (the GAME CHANGER trial): an open-label, parallel-group, randomised trial
头孢地尔与标准疗法治疗医院获得性和医疗保健相关性革兰氏阴性菌血流感染（GAME CHANGER试验）：一项开放标签、平行分组、随机试验
David L Paterson,Helmi Sulaiman,Po-Yu Liu,Mark D Chatfield,Mesut Yilmaz,Zeti Norfidiyati Salmuna,Mohd Zulfakar Mazlan,Siriluck Anunnatsiri,Rujipas Sirijatuphat,Darunee Chotiprasitsakul,David C Lye,Jyoti Somani,Shirin Kalimuddin,Abdullah T Aslan,Visanu Thamlikitkul,Yi-Tzu Lee,Ya-Sung Yang,Yi-Tsung Lin,Wan Nurliyana Wan Ramli,Chien-Hao Tseng,Sophia Archuleta,Yvonne Fu Zi Chan,Brian M Forde,Hugh Wright,Adam G Stewart,Kay A Ramsay,Weiping Ling,Vicki Rossi,Tiffany M Harris-Brown,Patrick N A Harrison behalf of the GAME CHANGER Trial Investigators
The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：p148
29
Efficacy and safety of ascending doses of orodispersible ivermectin co-administered with albendazole for Trichuris trichiura infections in preschool-aged children in Tanzania: a 坦桑尼亚学龄前儿童感染毛首鞭形线虫时，递增剂量口服分散片伊维菌素与阿苯达唑联合用药的疗效和安全性：一项单盲、随机、对照、剂量递增、2期试验
single-blind, randomised, controlled, dose-ranging, phase 2 trial
Viviane P Sprecher,Annina Schnoz,Stefan Biendl,Halima S Hussein,Sarah O Najim,Mohammed N Ali,Ibrahim S Mohammed,Said M Ali,Jan Hattendorf,Jennifer Keiser
The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：p160
30
Human monoclonal antibody MAM01 for protection against malaria in adults in the USA: a first-in-human, phase 1, dose-escalation, double-blind, placebo-controlled, adaptive trial
人源单克隆抗体MAM01保护美国成年人免受疟疾侵害：一项首次人体、1期、剂量递增、双盲、安慰剂对照、适应性试验
Kirsten E Lyke,Andrea A Berry,Matthew B Laurens,Jennifer Winkler,Sudhaunshu Joshi,Abra Rachida Koudjra,Lauryn Butler,Peter F Billingsley,Tales Pascini,Asha Patil,B Kim Lee Sim,Grace Fitzgerald,Julie Riegel,Kayla Andrews,Micha Levi,Aparna B Anderson,Charles D Wells,Hong Liu,James Huleatt,R Scott Miller
The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：p170
31
Characterising household transmission dynamics of clade Ib mpox in Burundi: a prospective cohort study
布隆迪Ib分支猴痘家庭传播动力学特征：一项前瞻性队列研究
Raoul Kamadjeu,Ferdinand Nsengimana,Manassé Nimpagaritse,Edna Moturi,Eric Kezakarayagwa,Rose Nkiko,Jonas Ngendakumana,Rémy Nimubona,Liliane Nkengurutse,Hamady Ba,Dionis Nizigiyimana,Paul Ngwakum,Mame Selbee Diouf,France Bégin,Joseph Nyandwi,Douglas James Noble
The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：p182
32
Long-term consequences of monkeypox virus infection or modified vaccinia virus Ankara vaccination in Belgium (MPX-COHORT and POQS-FU-PLUS): a 24-month prospective and retrospective cohort study
比利时猴痘病毒感染或改良痘苗病毒安卡拉株疫苗接种的长期后果（MPX-COHORT和POQS-FU-PLUS）：一项为期24个月的前瞻性和回顾性队列研究
Christophe Van Dijck,Nicole Berens-Riha,Luca M Zaeck,Cécile Kremer,Jacob Verschueren,Jasmine Coppens,Fien Vanroye,Elisabeth Willems,Evi Bosman,Natalie De Cock,Bart Smekens,Leen Vandenhove,Odin Goovaerts,Anke Van Hul,Janne Wouters,Bart K M Jacobs,Stefanie Bracke,Matilde Hens,Isabel Brosius,Elise De Vos,Eugene Bangwen,Sarah Houben,Achilleas Tsoumanis,Pedro Henrique Lopes Ferreira Dantas,Jojanneke Rutgers,Amber Lipman,Koen Wijnans,Patrick Soentjens,Emmanuel Bottieau,Chris Kenyon,Johan van Griensven,Thijs Reyniers,Niels Horst,Kevin K Ariën,Marjan Van Esbroeck,Andrea Torneri,Koen Vercauteren,Wim Adriaensen,Rory D de Vries,Joachim Mariën,Laurens Liesenborghs
The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：p190
33
Long-term risk of tuberculosis among individuals with Xpert Ultra trace screening results in Uganda: a longitudinal follow-up study
乌干达Xpert Ultra微量筛查结果阳性个体患结核病的长期风险：一项纵向随访研究
Joowhan Sung,Mariam Nantale,Annet Nalutaaya,Patrick Biché,James Mukiibi,Joab Akampurira,Rogers Kiyonga,Francis Kayondo,Michael Mukiibi,Caitlin Visek,Caleb E Kamoga,David W Dowdy,Achilles Katamba,Emily A Kendall
The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：p203
Review（综述）
34
Invasive group A streptococcal infections: lessons learned from the 2022–23 upsurge
侵袭性A组链球菌感染：从2022-23年激增中吸取的教训
Alix Flamant,Alicia Demirjian,Theresa Lamagni,Julie Toubiana,Pierre R Smeesters,Jérémie F Cohen
The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：e91
35
A clinical practice guideline for tuberculous meningitis
结核性脑膜炎临床实践指南
Joseph Donovan,Fiona V Cresswell,Elizabeth W Tucker,Angharad G Davis,Ursula K Rohlwink,Julie Huynh,Regan Solomons,James A Seddon,Nathan C Bahr,Arjan van Laarhoven,Suzanne T Anderson,Sanjay K Jain,Felicia C Chow,Sophie Pattison,James E Scriven,Gabriela Singh,Rob E Aarnoutse,Jan-Willem C Alffenaar,Sofiati Dian,Abi Manesh,Robin Basu Roy,Varinder Singh,Ronald van Toorn,Caryn M Upton,Reinout van Crevel,Kelly E Dooley,Diana Gibb,David Meya,Robert J Wilkinson,Ewelina Rogozińska,Usha K Misra,Anthony Figaji,Guy E Thwaites
The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：e96
36
Towards shorter therapy for candidaemia: defining uncomplicated candidaemia in adults
缩短念珠菌血症疗程：界定成人非复杂性念珠菌血症
Ilana Reinhold,Susanne Picardi,Blasius Liss,Danila Seidel,Jannik Stemler,Philipp Koehler,Tamara Ruegamer,Rosanne Sprute,Oliver A Cornely
The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：e112
Personal View（个人观点）
37
A transformation in cholera surveillance
霍乱监测的变革
Amanda K Debes,Erin T Baumgartner,Kendra N Williams,David A Sack
The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：e124
Clinical Picture（临床图像）
38
Paediatric ocular toxocariasis with relentless progression despite negative metagenomic testing
尽管宏基因组检测呈阴性，但儿科眼弓蛔虫病仍持续进展
Diya Shah,Shiama Balendra,Harry Petrushkin,Anamika Patel
The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：e130
THE LANCET Infectious Diseases. Volume 26Number 3
柳叶刀传染病学 26卷 3期
https://www.thelancet.com/journals/laninf/issue/current
EDITORIAL（社论）
1
Promises and challenges of AI in infectious diseases
人工智能在传染病领域的承诺与挑战
The Lancet Infectious Diseases
The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：p213
COMMENT（述评）
2
More real-world evidence for RSV vaccines in the global community
全球范围社区呼吸道合胞病毒（RSV）疫苗的更广泛的现实证据
Kristina L Bajema,Wesley H Self
The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：p214
3
Rapid diagnostic antigen tests for mpox and the need for decentralised testing—not quite there yet
猴痘快速诊断抗原检测及分散检测的必要性——尚待完善
Daniel Mukadi-Bamuleka,Kevin K Ariën
The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：p215
4
Solving the data bottleneck for artificial intelligence in infectious diseases
解决传染病人工智能领域的数据瓶颈问题
Cesar de la Fuente-Nunez
The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：p217
5
Artificial intelligence and One Health: potential for spillover prediction?
人工智能与“同一健康”理念：能否预测病原体外溢？
Marion Koopmans,Istvan Csabai,Daniel Remondini,Emma Snary,Frank Aarestrup
The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：p219
6
Artificial intelligence in the development of vaccines for infectious diseases
人工智能在传染病疫苗研发中的应用
Steve Black,Shabir A Madhi,Rino Rappuoli
The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：p221
7
Peer review at The Lancet Infectious Diseases in 2025
2025年《柳叶刀-传染病学》期刊专家评审
Ursula Hofer
The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：p223
8
Thank you to The Lancet Infectious Diseases statistical and peer reviewers in 2025
感谢2025年《柳叶刀-传染病学》期刊的统计学及评审专家
The Lancet Infectious Diseases Editors
The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：e132
CORRESPONDENCE（读者来信）
9
Methodological considerations in the attribution of long COVID to first or second infection
首次或二次感染导致长期新冠症状的方法学考量
Sara Carazo,Danuta M Skowronski,Manale Ouakki,Gaston De Serres
The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：e139
10
Methodological considerations in the attribution of long COVID to first or second infection – Authors' reply
首次或二次感染导致长期新冠症状的方法学考量——作者回复
Bingyu Zhang,Qiong Wu,Ravi Jhaveri,Christopher B Forrest,Yong Chen
The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：e141
11
Humoral immunity after LP.8.1 monovalent vaccines against a broad range of SARS-CoV-2 variants including XEC, LP.8.1, NB.1.8.1, XFG, and BA.3.2
LP.8.1单价疫苗针对包括XEC、LP.8.1、NB.1.8.1、XFG和BA.3.2在内的多种SARS-CoV-2变异株的体液免疫应答
Yu Kaku,Mizuka Fujiwara,Keiya Uriu,Maximilian Stanley Yo,Shusuke Kawakubo,Jumpei Ito,Naoya Itoh,Yoshifumi Uwamino,Fumitake Saito,Hironori Satoh,The Genotype to Phenotype Japan (G2P-Japan) Consortium,Kei Sato
The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：e142
12
Precision diagnostics for MBLs: the true game changer in treating antimicrobial resistance
金属β-内酰胺酶精准诊断：治疗抗菌药物耐药性的真正变革者
Brenda A Warecki,María F Mojica,Alejandro J Vila,Robert A Bonomo
The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：e144
13
Precision diagnostics for MBLs: the true game changer in treating antimicrobial resistance – Authors' reply
金属β-内酰胺酶精准诊断：治疗抗菌药物耐药性的真正变革者——作者回复
David L Paterson,Abdullah T Aslan,Patrick N A Harris
The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：e145
CORRECTIONS（更正）
14
Correction to Lancet Infect Dis 2025; published online Dec 9. https://doi.org/10.1016/S1473-3099(25)00659-0
《柳叶刀-传染病学》2025年发表文章勘误；在线发表于12月9日。https://doi.org/10.1016/S1473-3099(25)00659-0
The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：e146
15
Correction to Lancet Infectious Diseases 2026; published online Jan 20. https://doi.org/10.1016/S1473-3099(25)00773-X
《柳叶刀-传染病学》2026年发表文章勘误；在线发表于1月20日。https://doi.org/10.1016/S1473-3099(25)00773-X
The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：e146
NEWSDESK（新闻台）
16
Rabies an increasing threat in Ukraine
乌克兰狂犬病威胁日益加剧
Ed Holt
The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：e147
17
People needing trachoma interventions at record low
需要沙眼干预措施的人数创历史新低
Timothy Jesudason
The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：e148
18
Uneven STI response in EU/EEA countries
欧盟/欧洲经济区国家性传播感染应对措施不均衡
Sanjeet Bagcchi
The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：e149
19
Controversial HBV vaccine trial in Guinea-Bissau halted
几内亚比绍有争议的乙型肝炎病毒疫苗试验被叫停
Talha Burki
The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：e150
20
Research in brief
研究简讯
Priya Venkatesan
The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：e151
OBITUARY（讣告）
21
Ivan Hirsch
伊万·赫希
Sanjeet Bagcchi
The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：p224
PROFILE（人物介绍）
22
Reem Abu Shomar— championing water safety in Gaza
里姆·阿布·舒马尔——加沙地带水安全倡导者
Tony Kirby
The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：p225
MEDIA WATCH（媒体观察）
Book（书籍）
23
A prescription for public health literacy
提升公众健康素养的良方
Vijay Shankar Balakrishnan
The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：p226
Book（书籍）
24
Imagining the inevitable
想象不可避免之事
Cahal McQuillan
The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：p227
Film（电影）
25
Women's autonomy, safe sex and HIV prevention
女性自主权、安全性行为与艾滋病预防
Sanjeet Bagcchi
The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：p228
ARTICLES（论著）
26
Vaccine effectiveness of a bivalent respiratory syncytial virus (RSV) pre-F vaccine against RSV-associated hospital admission among adults aged 75–79 years in England: a multicentre, test-negative, case–control study
英国75-79岁成年人中双价呼吸道合胞病毒（RSV）预融合F蛋白疫苗对RSV相关住院的有效性：一项多中心、检测阴性、病例对照研究
Rebecca Symes,Heather J Whitaker,Shazaad Ahmad,David Arnold,Suryabrata Banerjee,Cariad M Evans,Robin Gore,Jennifer Hart,Katy Heaney,Onn Min Kon,Anne Melhuish,Munira Ortale Zogaib,Emanuela Pelosi,Najib M Rahman,Gerrit Woltmann,Tricia McKeever,Maria Zambon,Conall H Watson,Wei Shen Lim,Jamie Lopez Bernalon behalf of the HARISS network collaborators
The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：p229
27
Oral itraconazole versus oral voriconazole for treatment-naive patients with chronic pulmonary aspergillosis in India (VICTOR-CPA trial): a single-centre, open-label, randomised, controlled, superiority trial
印度治疗初治慢性肺曲霉病患者口服伊曲康唑与口服伏立康唑的对比研究（VICTOR-CPA试验）：一项单中心、开放标签、随机、对照、优效性试验
Inderpaul Singh Sehgal,Ritesh Agarwal,Sahajal Dhooria,Kuruswamy Thurai Prasad,Valliappan Muthu,Ashutosh Nath Aggarwal,Shivaprakash M Rudramurthy,Mandeep Garg,Arunaloke Chakrabarti
The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：p239
28
Accounting for non-adherence to assigned antibiotic treatment duration for bloodstream infection (BALANCE): a post-hoc analysis of a randomised clinical trial
血流感染抗生素治疗疗程依从性考量（BALANCE）：一项随机临床试验的事后分析
Sean W X Ong,Ruxandra Pinto,Robert K Mahar,Asgar Rishu,Joshua S Davis,Robert A Fowler,Steven Y C Tong,Nick Danemanfor the BALANCE trial consortium
The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：p250
29
Field evaluation of a rapid antigen test for mpox in the Democratic Republic of the Congo and Uganda: a multicentre, prospective, diagnostic accuracy study
刚果民主共和国和乌干达猴痘快速抗原检测的现场评估：一项多中心、前瞻性、诊断准确性研究
Barnabas Bakamutumaho,David Lupande Mwenebitu,Winters Muttamba,Ingrid Ampeire,Henry Kyobe Bosa,Esto Bahizire,Bertin Casinga Bisimwa,Andrew Obuku,Misaki Wayengera,Alison Sandeman,Matthew T G Holden,Patrick D M C Katoto,Bruce Kirenga,Deborah A Williamson,Wilber Sabiiti
The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：p260
30
Complications and mortality of typhoid fever: an updated global systematic review and meta-analysis
伤寒热的并发症与死亡率：一项更新的全球系统综述与荟萃分析
Shruti Murthy,Nienke N Hagedoorn,Suzanne Faigan,Meera D Rathan,Christian S Marchello,John A Crump
The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：p270
31
Global, regional, and national burden of Chagas disease, 1990–2023: a systematic analysis for the Global Burden of Disease Study 2023
1990-2023年全球、区域和国家层面查加斯病负担：2023年全球疾病负担研究的系统分析
GBD 2023 Chagas Disease and RAISE Study Collaborators
The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：p284
32
Safety, tolerability, and immunogenicity of the ChAdOx1 RVF vaccine against Rift Valley fever among healthy adults in Uganda: a single-centre, single-blind, randomised, placebo-controlled, dose-escalation, phase 1 trial
乌干达健康成年人中ChAdOx1裂谷热疫苗的安全性、耐受性和免疫原性：一项单中心、单盲、随机、安慰剂对照、剂量递增的1期试验
Zacchaeus Anywaine,Jennifer Serwanga,Abu-Baker Mustapher Ggayi,Andrew Max Abaasa,Daniel Wright,Ben Gombe,Peter Ejou,Tamara Namata,Antony Kigozi,Naboth Tukamwesiga,Vincent Basajja,Violet Ankunda,Dora Jocelyn Mulondo,Florence Nambaziira,Ayoub Kakande,Wilson Kakeeto,Phiona Nabaggala,Daniel Jenkin,Alison Lawrie,Pedro Folegatti,Nguyen Tran,Christian Hansen,Alison M Elliott,Adrian V S Hill,George M Warimwe,Pontiano Kaleebu
The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：p302
33
Immunogenicity and safety of an 18-month booster dose of the VLA15 Lyme borreliosis vaccine candidate after primary immunisation in children, adolescents, and adults in the USA: a randomised, observer-blind, placebo-controlled, phase 2 trial
美国儿童、青少年和成人基础免疫后18个月VLA15莱姆病疫苗候选物的加强免疫接种的免疫原性和安全性：一项随机、观察者盲法、安慰剂对照的2期试验
Laura Wagner,Michaela Obersriebnig,Romana Hochreiter,Vera Kadlecek,Julian Larcher-Senn,Lisa Hegele,Jason D Maguire,Timothy Murphy,Ulla Derhaschnig,Nicole Bézay,Juan Carlos Jaramillo,Susanne Eder-Lingelbach,Marc Messier
The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：p314
SERIES（研讨会）
Artificial Intelligence and Infectious Diseases
人工智能与传染病
34
Artificial intelligence and infectious diseases: an evidence-driven conceptual framework for research, public health, and clinical practice
人工智能与传染病：基于证据的研究、公共卫生和临床实践概念框架
Anna Odone,Chiara Barbati,Silvia Amadasi,Tanja Schultz,David B Resnik
The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：e152
35
Artificial intelligence and infectious disease diagnostics: state of the art and future perspectives
人工智能与传染病诊断：现状与未来展望
Luca Miglietta,Timothy M Rawson,Ronald Galiwango,Alex Tasker,Damien K Ming,Darlington Akogo,Cecilia Ferreyra,Eric O Aboagye,N Claire Gordon,Carolina Garcia-Vidal,Jesus Rodriguez-Manzano,Alison H Holmes
The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：e168
36
Artificial intelligence and infectious diseases: tackling antimicrobial resistance, from personalised care to antibiotic discovery
人工智能与传染病：应对抗菌药物耐药性，从个性化治疗到抗生素发现
Alex Howard,Nada Reza,Peter L Green,Mo Yin,Erin Duffy,Henry C Mwandumba,Alessandro Gerada,William Hope
The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：e181
REVIEW（综述）
37
Community-acquired respiratory virus infections in patients with haematological malignancies or undergoing haematopoietic cell transplantation: updated recommendations from the 10th European Conference on Infections in Leukaemia
血液系统恶性肿瘤患者或接受造血细胞移植患者社区获得性呼吸道病毒感染：第10届欧洲白血病感染会议更新建议
Marie von Lilienfeld-Toal,Fareed Khawaja,Francesca Compagno,Christine Robin,José-Luis Piñana,Simone Cesaro,Hermann Einsele,Per Ljungman,David Navarro,Michael Boeckh,Roy F Chemaly,Hans H Hirsch
The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：e193
CLINICAL PICTURE（临床图像）
38
Mycoplasma hominis toe osteomyelitis: a rare and unusual bone infection
人型支原体足趾骨髓炎：一种罕见且不寻常的骨感染
Cheryl Keel,Pauleen McSherry,Rebecca Thombre,Sendurann Nadarajah,Rediat Tewolde,Owen B
Spiller,Baharak Afshar
The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：e207
THE LANCET Infectious Diseases. Volume 26Number 4
柳叶刀传染病学 26卷 4期
https://www.thelancet.com/journals/laninf/issue/current
EDITORIAL(社论)
1
GoGoVax dispels hopes for gonorrhoea vaccination
GoGoVax让淋病疫苗的希望破灭
The Lancet Infectious Diseases
The Lancet Infectious Diseases. Apr 2026，Vol 26(4)：p329
COMMENT（述评）
2
Do the benefits of universal screening outweigh the harms?
全民筛查的益处是否大于害处？
Alanna N Gillespie,Emma Webb,Valerie Sung
The Lancet Infectious Diseases. Apr 2026，Vol 26(4)：p330
3
Chikungunya in Brazil: vaccination strategies informed by mathematical modelling
巴西基孔肯雅热：基于数学建模的疫苗接种策略
José Lourenço,Marta Giovanetti
The Lancet Infectious Diseases. Apr 2026，Vol 26(4)：p331
4
Chikungunya adolescent vaccination and the distinct risk–benefit landscapes
青少年接种基孔肯雅热疫苗及独特的风险-获益情况
Ernesto T A Marques,Simon Barratt-Boyes
The Lancet Infectious Diseases. Apr 2026，Vol 26(4)：p333
5
Circulation of clade Ib mpox outside of Africa—are we prepared?
非洲以外地区Ib分支猴痘的传播——我们准备好了吗？
Seth D Judson,Claude Kwe Yinda,Franziska K Kaiser,Daniel S Chertow,Emmie de Wit,James O Lloyd-Smith,Vincent J Munster
The Lancet Infectious Diseases. Apr 2026，Vol 26(4)：p334
6
I worked at WHO: the USA leaving will not make America healthier
我曾在世卫组织工作：美国退出不会让美国更健康
Krutika Kuppalli
The Lancet Infectious Diseases. Apr 2026，Vol 26(4)：p336
CORRESPONDENCE（读者来信）
7
Maternal views on RSV vaccination in the UK's second season
英国第二季呼吸道合胞病毒疫苗接种的产妇观点
Shaun O'Hagan,Steve Cunningham,Simon B Drysdale,Helen E Groves,Samantha Hunt,Dalia Iskander,Xinxue Liu,Mark D Lyttle,Chengetai D Mpamhanga,Thomas Waterfield,Thomas C Williams,Robin Marlow,Damian Rolandon behalf of the PERUKI & BronchStart/Stop Collaboration
The Lancet Infectious Diseases. Apr 2026，Vol 26(4)：e209
8
Overcoming immune imprinting with the COVID-19 LP.8.1 mRNA boosters
利用COVID-19 LP.8.1 mRNA加强针克服免疫印记
Ninaad Lasrado,Annika Rössler,Katherine Molloy,Isabella McConnell,Ritobhas Bhowmik,Francisco Armando Granados-Contreras,Jessica Wu,Alejandra Waller-Pulido,Samuel J Nangle,Erica Borducchi,Ai-ris Y Collier,Dan H Barouch
The Lancet Infectious Diseases. Apr 2026，Vol 26(4)：e212
CORRECTIONS（更正）
9
Correction to Lancet Infect Dis 2025; published online Nov 27.
https://doi.org/10.1016/S1473-3099(25)00605-X
《柳叶刀-传染病学》2025年刊载内容更正；在线发布于11月27日
The Lancet Infectious Diseases. Apr 2026，Vol 26(4)：e214
10
Correction to Lancet Infect Dis 2026; 26: 343–61
《柳叶刀-传染病学》2026年刊载内容更正；26卷：343-61页
The Lancet Infectious Diseases. Apr 2026，Vol 26(4)：e214
11
Correction to Lancet Infect Dis 2026; published online Jan 23. https://doi.org/10.1016/S1473-3099(25)00730-3
《柳叶刀-传染病学》2026年刊载内容更正；在线发布于1月23日
The Lancet Infectious Diseases. Apr 2026，Vol 26(4)：e214
12
Correction to Lancet Infect Dis 2026; published online Jan 28. https://doi.org/10.1016/S1473-3099(25)00747-9
《柳叶刀-传染病学》2026年刊载内容更正；在线发布于1月28日
The Lancet Infectious Diseases. Apr 2026，Vol 26(4)：e214
NEWSDESK（新闻台）
13
UK loses measles elimination status as cases rise
随着病例增加，英国失去麻疹消除地位
Priya Venkatesan
The Lancet Infectious Diseases. Apr 2026，Vol 26(4)：e215
14
Brazil launches implementation study of lenacapavir
巴西启动来那卡帕韦实施研究
Tony Kirby
The Lancet Infectious Diseases. Apr 2026，Vol 26(4)：e216
15
Clade Ib mpox in southwest Indian Ocean islands
西南印度洋岛屿出现Ib分支猴痘
Esther Nakkazi
The Lancet Infectious Diseases. Apr 2026，Vol 26(4)：e217
16
EMA approves combined COVID-19 and flu mRNA vaccine
欧洲药品管理局批准COVID-19和流感联合mRNA疫苗
Talha Burki
The Lancet Infectious Diseases. Apr 2026，Vol 26(4)：e218
17
Research in brief
研究简讯
Priya Venkatesan
The Lancet Infectious Diseases. Apr 2026，Vol 26(4)：e219
OBITUARY（讣告）
18
Nicholas John White
尼古拉斯·约翰·怀特
Sanjeet Bagcchi
The Lancet Infectious Diseases. Apr 2026，Vol 26(4)：p339
PROFILE（人物简介）
19
Katharina Kranzer—led by curiosity, committed to capacity
卡塔琳娜·克兰泽——受好奇心驱使，致力于提升能力
Tony Kirby
The Lancet Infectious Diseases. Apr 2026，Vol 26(4)：p340
MEDIA WATCH（媒体观察）
Film（电影）
20
Leishmaniasis: a story of two continents
利什曼病：两个大陆的故事
Vijay Shankar Balakrishnan
The Lancet Infectious Diseases. Apr 2026，Vol 26(4)：p341
Book（书籍）
21
Finding your voice in a world of uncertainty
在不确定的世界中找到自己的声音
Carrie Fielden
The Lancet Infectious Diseases. Apr 2026，Vol 26(4)：p342
ARTICLES（论著）
22
Global burden of lower respiratory infections and aetiologies, 1990–2023: a systematic analysis for the Global Burden of Disease Study 2023
1990-2023年下呼吸道感染的全球负担及病因：2023年全球疾病负担研究的系统分析
GBD 2023 Lower Respiratory Infections and Antimicrobial Resistance Collaborators
GBD 2023下呼吸道感染和抗菌素耐药性协作组
The Lancet Infectious Diseases. Apr 2026，Vol 26(4)：p343
23
Effectiveness of the maternal RSVpreF vaccine against severe disease in infants in Scotland, UK: a national, population-based case–control study and cohort analysis
英国苏格兰地区母体RSVpreF疫苗对婴儿严重疾病的保护效果：一项全国性、基于人群的病例对照研究和队列分析
Isobel McLachlan,Chris Robertson,Kirsty E Morrison,Ross McQueenie,Safraj Shahul Hameed,Cheryl Gibbons,Rachael Wood,Rachel Merrick,Louisa Pollock,Antonia Ho,Ting Shi,Thomas C Williams,Sir Aziz Sheikh,Jim McMenamin,Sam Ghebrehewet,Kimberly Marsh
The Lancet Infectious Diseases. Apr 2026，Vol 26(4)：p362
24
Post-COVID-19 resurgence of Mycoplasma pneumoniae infections in French children (ORIGAMI): a retrospective and prospective multicentre cohort study
法国儿童COVID-19后支原体肺炎感染的复现（ORIGAMI）：一项回顾性和前瞻性多中心队列研究
Anaïs Chosidow,Zoha Maakaroun-Vermesse,Vichita Ok,Cécile Delecroix,Pascal Le Roux,Marie-Aliette Dommergues,Justine de Larminat,Eric Jeziorski,Pauline Ronjat,Léa Jaume,Anne Welfringer-Morin,Cécile Bébéar,Maud Gits-Muselli,Delphine Viriot,Charles-Joris Roux,Stéphane Bechet,Anne-Sophie Romain,Mathie Lorrot,Robert Cohen,Corinne Levy,Jérémie F Cohenon behalf of the ORIGAMI Study Group
The Lancet Infectious Diseases. Apr 2026，Vol 26(4)：p374
25
Lessons derived from a 3-year congenital cytomegalovirus screening programme in Israel: a prospective population-based cohort study
以色列先天性巨细胞病毒筛查项目的3年经验教训：一项前瞻性基于人群的队列研究
Smadar Eventov Friedman,Noa Ofek Shlomai,Esther Oiknine-Djian,Tal Sido,Oren Gordon,Sraya Greenberger,Hadar Horowitz,Lior Merav,Stav David Mehaber,Orit Caplan,Miriam Geal-Dor,Natalia Simanovsky,Diana Averbuch,Colin Kunzweiler,Yosefa Hefter,John Diaz-Decaro,Ora Paltiel,Moran Yassour,Dana G Wolf
The Lancet Infectious Diseases. Apr 2026，Vol 26(4)：p384
26
Comparison of the performance and costs of testing algorithms using rapid diagnostic tests for detection and treatment of syphilis among pregnant individuals and men who have sex with men: a modelling study
使用快速诊断检测方法对孕妇和男男性行为者进行梅毒检测和治疗的不同检测算法的性能和成本比较：一项建模研究
Ying Zhang,Eric P F Chow,Lei Zhang,Christopher K Fairley,Jason J Ong
The Lancet Infectious Diseases. Apr 2026，Vol 26(4)：p394
27
The epidemiology of chikungunya virus in Brazil and the potential impact of vaccines: a mathematical modelling study
巴西基孔肯雅热病毒的流行病学及疫苗的潜在影响：一项数学建模研究
Oscar Cortes-Azuero,Megan O'Driscoll,Gabriel Ribeiro dos Santos,Ronaldo de Jesus,Shirlene T S de Lima,Danny Scarponi,Christinah Mukandavire,Arminder Deol,Moritz U G Kraemer,William M de Souza,Henrik Salje
The Lancet Infectious Diseases. Apr 2026，Vol 26(4)：p406
28
Safety and immunogenicity of a live-attenuated chikungunya virus vaccine in adolescents: final results from a 12-month, double-blind, randomised, placebo-controlled, phase 3 trial in endemic areas of Brazil
青少年接种减毒活基孔肯雅热病毒疫苗的安全性和免疫原性：巴西流行地区一项为期12个月、双盲、随机、安慰剂对照的3期试验最终结果
Vera Buerger,Andrea Pfeiffer,Petra Schoengrundner,Jutta Seebacher,Romana Hochreiter,Karin Kosulin,Oliver Zoihsl,Petronela Weisova,Robert Mader,Ana Paula Loch,Eolo Morandi Jr,Mauricio Lacerda Nogueira,Carlos Alexandre Antunes de Brito,Julio Croda,Mauro Martins Teixeira,Ivo Castelo-Branco Coelho,Ricardo Gurgel,Allex Jardim da Fonseca,Marcus Vinícius Guimarães de Lacerda,Edson Duarte Moreira Jr,Ana Paula Rocha Veiga,Susanne Eder-Lingelbach,Juan Carlos Jaramillo
The Lancet Infectious Diseases. Apr 2026，Vol 26(4)：p417
29
National burden of and optimal vaccine policy for Japanese encephalitis virus in Bangladesh: a seroprevalence and modelling study
孟加拉国日本脑炎病毒的全国负担及最佳疫苗接种政策：一项血清流行率和建模研究
Mariana Perez Duque,Kishor K Paul,Rebeca Sultana,Gabriel Ribeiro dos Santos,Megan O'Driscoll,Abu M Naser,Mahmudur Rahman,Mohammad Shafiul Alam,Hasan M Al-Amin,Mohammed Z Rahman,Mohammad E Hossain,Repon C Paul,Elias Krainski,Stephen P Luby,Simon Cauchemez,Jessica Vanhomwegen,Emily S Gurley,Henrik Salje
The Lancet Infectious Diseases. Apr 2026，Vol 26(4)：p429
REVIEW（综述）
30
Autoantibodies in long COVID: a systematic review
长新冠中的自身抗体：一项系统综述
Fabian Wilhelm,Janne Cadamuro,Sylvia Mink
The Lancet Infectious Diseases. Apr 2026，Vol 26(4)：e220
31
Core outcome measurement set for clinical trials in dengue: an international Delphi consensus study (DEN-CORE)
登革热临床试验核心结局测量指标集：一项国际德尔菲共识研究（DEN-CORE）
Sophie Yacoub,Anastasia Demidova,Xin Hui S Chan,Ali Ajam,Dina Baimukhambetova,Andreij Horn,Evgeniia Kakotkina,Mark Kosenko,Aigun Mursalova,Jennifer Ilo Van Nuil,Chi Le Phuong,Lin Xiao,Sudeep Adhikari,Juan David Alzate Alvarez,Kathryn B Anderson,Panisadee Avirutnan,Stephanie Buchholz,Richa Chandra,Aileen Y Chang,Ho Quang Chanh,Mónika Patricia Consuegra Rodríguez,Vanessa Daniel,Janet V Diaz,Claudia Figueiredo-Mello,Rosa Margarita Gelvez-Ramírez,Tran Bang Huyen,Evelyne Kestelyn,Phung Khanh Lam,Stije J Leopold,Ruobing Li,Tran Luu,David Chien Boon Lye,Angela McBride,Isabelle Meyer-Andrieux,Nathaniel J Moorman,Nguyet Minh Nguyen,Sharifah Faridah Syed Omar,Hang Cheng Ong,Eng Eong Ooi,Ekaterina Pazukhina,Sarah L Pett,Diego Bastos Porto,Giri S Rajahram,Marc Rogers,Elsa Rojas,James Rosen,Jamie Rylance,William H K Schilling,Andre M Siqueira,Peter Sjö,Alfonso Sucerquia-Hernandez,Dong Thi Hoai Tam,Mauro Martins Teixeira,Andreas Tietz,Huynh Trung Trieu,Annalise Unsworth,Luis Villar,Adam Tully Waickman,James A Watson,Bridget A Wills,Po Ying Chia,Patricia Brasil,Thomas Jaenisch,Lucy Lum,Gathsaurie Neelika Malavige,Steven McGloughlin,Bharath Kumar Tirupakuzhi Vijayaraghavan,Laura Merson,Daniel Munblitthe DEN-CORE Study Group
The Lancet Infectious Diseases. Apr 2026，Vol 26(4)：e231
PERSONAL VIEW（个人观点）
32
Breaking the under-reporting cycle for zoonotic diseases in low-income and middle-income countries through national-level integration of community-based surveillance and response: insights from Cameroon, Chad, Côte d’Ivoire, and Mali
通过国家层面整合社区监测和响应，打破低收入和中等收入国家人畜共患病报告不足的循环：来自喀麦隆、乍得、科特迪瓦和马里的见解
Katherine E L Worsley-Tonks,Mahamat Fayiz Abakar,Zanan Coulibaly,Marie Paulette Deya-Yang,Linda Esso,Jean Marc Kameni Feussom,Vessaly Kallo,Zakaria Keita,Monique Lechenne,Magloire Tchamba Kombou,Inès Emah Manda,Christiane Mangou,Stephanie Mauti,Aime Gilert Mbonda Noula,Rodrigue Poueme Namegni,Perrine Parize,Mathurin Cyrille Tejiokem,Isaac Tiembre,Abdallah Traoré,Jakob Zinsstag,Hervé Bourhy
The Lancet Infectious Diseases. Apr 2026，Vol 26(4)：e245
GRAND ROUND（大查房）
33
Paediatric case of invasive group A streptococcal necrotising myositis: diagnostic challenges and lessons learned
儿童侵袭性A组链球菌坏死性肌炎病例：诊断挑战和经验教训
Suraya Yusuf,Michael James Carter,Jenny Woodruff,Peter Kalu,Justin Conrad Rosen Wormald,Claire Sethu
The Lancet Infectious Diseases. Apr 2026，Vol 26(4)：e259
CLINICAL PICTURE（临床图像）
34
Bullous haemorrhagic cellulitis caused by Escherichia coli in a patient with cirrhosis
肝硬化患者由大肠杆菌引起的大疱性出血性蜂窝织炎
Irene Rivera-Ruiz,Paloma Elma Alañón-Martínez,Elisa Vidal-Verdú
The Lancet Infectious Diseases. Apr 2026，Vol 26(4)：e268
2026-03-26
THE LANCET Infectious Diseases. Volume 26Number 1
柳叶刀传染病学 26卷 1期
https://www.thelancet.com/journals/laninf/issue/current
EDITORIAL(社论)
1
Urgent need for infection prevention and control in prisons
监狱中感染预防和控制的迫切需求
The Lancet Infectious Diseases
The Lancet Infectious Diseases Vol 26(1):p1
COMMENT（述评）
2
Now is the time to integrate serology into routine infectious disease surveillance
现在是时候将血清学纳入常规传染病监测了
Simon Cauchemez
The Lancet Infectious Diseases Vol 26(1):p2
3
Reassessing sotrovimab's role in COVID-19: insights and implications
重新评估索托维单抗在新冠肺炎治疗中的作用：见解与启示
Daniele Focosi,Fabrizio Maggi
The Lancet Infectious Diseases Vol 26(1):p3
4
Shaping opportunities for future clinical trials in tuberculosis
为未来结核病临床试验创造机会
Ivan Noreña,Beno Mbeya,Joanitah Nalunjogi,Ombeni Chimbe,Norbert Heinrich
The Lancet Infectious Diseases Vol 26(1):p5
5
Diversifying antimalarial treatment for uncomplicated Plasmodium falciparum malaria in Uganda
乌干达针对无并发症恶性疟原虫疟疾的抗疟治疗多样化
Arjen M Dondorp
The Lancet Infectious Diseases Vol 26(1):p6
6
A safe start for PfSPZ Vaccine, but efficacy in children remains elusive
PfSPZ疫苗安全起步，但在儿童中的疗效仍难以捉摸
Nicholas Aderinto,Temitomi Jane Oyedele
The Lancet Infectious Diseases Vol 26(1):p8
7
Rifasutenizol-based triple therapy for Helicobacter pylori infection
以利法苏替尼唑为基础的三联疗法治疗幽门螺杆菌感染
Jinnan Chen,Hong Lu
The Lancet Infectious Diseases Vol 26(1):p9
8
The smallest faith
最渺小的信念
Steven A Pergam
The Lancet Infectious Diseases Vol 26(1):p11
9
Negative results in long COVID clinical trials: choosing outcome measures for a heterogeneous disease
新冠肺炎长期症状临床试验的阴性结果：为异质性疾病选择预后指标
Lara Goxhaj,Lisa McCorkell,Femke van Rhijn-Brouwer,Letícia Soares,Julia Moore Vogel,Chloé de Canson
The Lancet Infectious Diseases Vol 26(1):p13
10
Strengthening global preparedness and response to arboviral disease threats: a call to action
加强全球应对虫媒病毒疾病威胁的准备和响应：行动呼吁
WHO Global Arbovirus Initiative Technical Advisory Group
世界卫生组织全球虫媒病毒倡议技术咨询小组
The Lancet Infectious Diseases Vol 26(1):p15
11
Introducing our cover artist for 2026: Daria Lada
介绍我们2026年的封面艺术家：达里亚·拉达
Marco De Ambrogi
The Lancet Infectious Diseases Vol 26(1):p17
Correspondence（读者来信）
12
Epidemiological and virological update on the emerging SARS-CoV-2 variant BA.3.2
新兴新冠病毒变异株BA.3.2的流行病学和病毒学最新情况
Lu Zhang,Nianzhen Chen,Amy Eichmann,Inga Nehlmeier,Anna-Sophie Moldenhauer,Metodi V Stankov,Christine Happle,Alexandra Dopfer-Jablonka,Georg M N Behrens,Markus Hoffmann,Stefan Pöhlmann
The Lancet Infectious Diseases Vol 26(1):e1
13
Effects of LP.8.1-adapted mRNA vaccination on SARS-CoV-2 variant neutralisation
Christine Happle,Markus Hoffmann,Metodi V Stankov,Inga Nehlmeier,Amy Eichmann,Torsten LP.8.1适应性mRNA疫苗接种对新冠病毒变异株中和作用的影响
Witte,Luis Manthey,Stefan Pöhlmann,Alexandra Dopfer-Jablonka,Georg M N Behrens
The Lancet Infectious Diseases Vol 26(1):e3
14
Artificial intelligence and spillover prediction: aligning innovation with empirical reality in One Health surveillance
人工智能与溢出预测：在“同一健康”监测中使创新与经验现实保持一致
Nader Ebrahimi,Amir Ghaemi
The Lancet Infectious Diseases Vol 26(1):e6
15
Artificial intelligence and spillover prediction: aligning innovation with empirical reality in One Health surveillance – Authors' reply
人工智能与溢出预测：在“同一健康”监测中使创新与经验现实保持一致——作者回复
Frank Aarestrup,Marion Koopmans
The Lancet Infectious Diseases Vol 26(1):e7
16
Time to tackle vaccine–HLA associations with artificial intelligence
是时候用人工智能解决疫苗-人类白细胞抗原关联问题了
Alexander J Mentzer,George Davey Smith,Teresa Lambe,Julian C Knight,Mary Carrington
The Lancet Infectious Diseases Vol 26(1):e8
Corrections（更正）
17
Correction to Lancet Infect Dis 2025; published online Oct 29.
《柳叶刀-传染病》2025年更正；在线发表于10月29日
https://doi.org/10.1016/S1473-3099(25)00466-9
The Lancet Infectious Diseases Vol 26(1):e9
18
Correction to Lancet Infect Dis 2025; published online Oct 27.
《柳叶刀-传染病》2025年更正；在线发表于10月27日
https://doi.org/10.1016/S1473-3099(25)00546-8
The Lancet Infectious Diseases Vol 26(1):e9
19
Correction to Lancet Infect Dis 2025; 25: 1084–96
《柳叶刀-传染病》2025年更正；25卷：1084-1096页
The Lancet Infectious Diseases Vol 26(1):e9
20
Correction to Lancet Infect Dis 2025; published online Nov 10.
《柳叶刀-传染病》2025年更正；在线发表于11月10日
https://doi.org/10.1016/S1473-3099(25)00550-X
The Lancet Infectious Diseases Vol 26(1):e9
Newsdesk（新闻台）
21
Highlights of IDWeek 2025
2025年IDWeek亮点
Phoebe Hall
The Lancet Infectious Diseases Vol 26(1):e10
22
WHO publishes update on global antibiotic resistance
世界卫生组织发布全球抗生素耐药性最新情况
Timothy Jesudason
The Lancet Infectious Diseases Vol 26(1):e11
23
European Commission to fund new medicines for dengue
欧盟委员会资助登革热新药研发
Sanjeet Bagcchi
The Lancet Infectious Diseases Vol 26(1):e12
24
Second report from the UK Covid-19 Inquiry
英国新冠肺炎调查第二次报告
Talha Burki
The Lancet Infectious Diseases Vol 26(1):e13
25
Infectious disease surveillance update
传染病监测最新情况
Cahal McQuillan
The Lancet Infectious Diseases Vol 26(1):e14
26
Research in brief
研究简讯
Priya Venkatesan
The Lancet Infectious Diseases Vol 26(1):e15
Obituary（讣告）
27
Jean Louis Abdourahim Ndiaye
让·路易斯·阿卜杜拉希姆·恩迪亚耶
Sanjeet Bagcchi
The Lancet Infectious Diseases Vol 26(1):p19
Profile（人物介绍）
28
Fortunate Machingura—tackling climate change and disease
福图纳特·马辛古拉——应对气候变化与疾病
Tony Kirby
The Lancet Infectious Diseases Vol 26(1):p20
Media Watch（媒体观察）
Book（书籍）
29
The social and political drivers behind pandemics
大流行背后的社会和政治驱动因素
Emma Louise Fabiani
The Lancet Infectious Diseases Vol 26(1):p21
Articles（论著）
30
Dynamics of endemic virus re-emergence in children in the USA following the COVID-19 pandemic (2022–23): a prospective, multicentre, longitudinal, immunoepidemiological surveillance study
新冠肺炎疫情后美国儿童地方性病毒重新出现的动态（2022-23年）：一项前瞻性、多中心、纵向、免疫流行病学监测研究
Hai Nguyen-Tran,Sang Woo Park,Matthew R Vogt,Perdita Permaul,Alicen B Spaulding,Michelle L Hernandez,Jennifer A Bohl,Sucheta Godbole,Tracy J Ruckwardt,Peter W Krug,Daniel L Moss,Alexandrine Derrien-Colemyn,Ananda Chowdhury,Gabrielle Dziubla,Lu Wang,Mike Castro,Sandeep R Narpala,Elizabeth R Longtine,Amy R Henry,Teri-T B Ngo,Leonid Dzantiev,George B Sigal,C Jessica Metcalf,David W Kimberlin,Samuel R Dominguez,Abraham Mittelman,Adrian B McDermott,Leonid A Serebryannyy,Bryan Grenfell,Kevin Messacar,Daniel C Douek
The Lancet Infectious Diseases Vol 26(1):p22
31
Sotrovimab versus usual care in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
索托维单抗与常规治疗对住院新冠肺炎患者的疗效对比（RECOVERY）：一项随机、对照、开放标签、平台试验
RECOVERY Collaborative Group
RECOVERY协作组
The Lancet Infectious Diseases Vol 26(1):p34
32
A 3-month clofazimine–rifapentine-containing regimen for drug-susceptible tuberculosis versus standard of care (Clo-Fast): a randomised, open-label, phase 2c clinical trial
含氯法齐明-利福喷丁的3个月方案与标准治疗方案治疗药物敏感性结核病的对比（Clo-Fast）：一项随机、开放标签、2c期临床试验
John Z Metcalfe,Isabelle R Weir,Kimberly K Scarsi,Alberto Mendoza-Ticona,Samuel Pierre,Luke Hall,Jorge Leon-Cruz,Elin M Svensson,Simon E Koele,Wadzanai Samaneka,Cecilia Kanyama,Maxwell Yohane,Neetal Nevrekar,Busisiwe Ntsalaze,Jean Bernard Marc,Melanie Goth,Gary Maartens,Richard Chaissonon behalf of the ACTG A5362 study team
The Lancet Infectious Diseases Vol 26(1):p46
33
Global policy responses to antimicrobial resistance, 2021–22: a systematic governance analysis of 161 countries and territories
2021-22年全球应对抗菌药物耐药性的政策反应：对161个国家和地区进行的系统性治理分析
Jay Patel,Sahar Saeedi Moghaddam,Sruthi Ranganathan,Neil Vezeau,Emily O'Neill,Anne Harant,Michael Stolpe,Lothar H Wieler,Tim Eckmanns,Devi Sridhar
The Lancet Infectious Diseases Vol 26(1):p55
34
Efficacies of artemether–lumefantrine, artesunate–amodiaquine, dihydroartemisinin–piperaquine, and artesunate–pyronaridine for the treatment of uncomplicated Plasmodium falciparum malaria in children aged 6 months to 10 years in Uganda: a randomised, open-label, phase 4 clinical trial
乌干达6个月至10岁儿童使用蒿甲醚-本芴醇、青蒿琥酯-阿莫地喹、双氢青蒿素-哌喹和青蒿琥酯-吡喃隆治疗无并发症恶性疟原虫疟疾的疗效：一项随机、开放标签、4期临床试验
Moses R Kamya,Joaniter I Nankabirwa,Chris Ebong,Victor Asua,Moses Kiggundu,Stephen Orena,Martin Okitwi,Stephen Tukwasibwe,Bosco Agaba,Daniel Kyabayinze,Jimmy Opigo,Damian Rutazana,Benjamin Binagwa,Edward Mugwanya,Shakira Babirye,Gloria Sebikaari,Patrick M Condo,Grace Appiah,Sam L Nsobya,Melissa D Conrad,Philip J Rosenthal,Leah F Moriarty,Adoke Yeka
The Lancet Infectious Diseases Vol 26(1):p67
35
Safety, tolerability, and protective efficacy of a radiation-attenuated, whole sporozoite malaria vaccine in children in Gabon: a randomised, double-blind, placebo-controlled, phase 2 trial
加蓬儿童使用辐射减毒全孢子虫疟疾疫苗的安全性、耐受性和保护效力：一项随机、双盲、安慰剂对照、2期试验
Selidji T Agnandji,Jeroen Bok,Ayodele Alabi,Anita L Kabwende,Armel Mbouna,Juste Bie,Eleonne Moukiti,Albert Lalremruata,Meral Esen,Andrea Kreidenweiss,Natasha KC,B Kim Lee Sim,Thomas L Richie,L W Preston Church,Matthew B B McCall,Stephen L Hoffman,Peter G Kremsner,Benjamin Mordmüller
The Lancet Infectious Diseases Vol 26(1):p79
36
Effectiveness of the TAK-003 dengue vaccine in adolescents during the 2024 outbreak in São Paulo, Brazil: a test-negative, case–control study
TAK-003登革热疫苗在2024年圣保罗暴发期间对青少年的有效性：一项测试阴性病例对照研究
Otavio T Ranzani,Felippe Lazar Neto,Lisany Krug Mareto,Thiago Sanches Brumatti,Roberto Dias de Oliveira,Patricia Vieira da Silva,Edinéia Ribeiro dos Santos,Tatiana Lang D' Agostini,Regiane A Cardoso De Paula,Natalie E Dean,Albert I Ko,Derek A T Cummings,Jason R Andrews,Matt D T Hitchings,Julio Croda
The Lancet Infectious Diseases Vol 26(1):p91
37
Rifasutenizol-based triple therapy versus bismuth plus clarithromycin-based triple therapy for first-line treatment of Helicobacter pylori infection in China (EVEREST-HP): a phase 3, multicentre, randomised, triple-dummy, double-blind, controlled, non-inferiority trial
以利法苏替尼唑为基础的三联疗法与铋剂加克拉霉素为基础的三联疗法作为中国幽门螺杆菌感染一线治疗的对比（EVEREST-HP）：一项3期、多中心、随机、三模拟、双盲、对照、非劣效性试验
Zhiqiang Song,Liya Zhou,Weihong Wang,Cheng Lan,Tongyu Tang,Jun Xie,Huizhen Fan,Xuehong Wang,Xiuli Zuo,Yin Zhu,Chengxia Liu,Yongsong Gu,Huang Feng,Xiang Gao,Qing Zhang,Hong Zhang,Jing Chen,Guozhu Geng,Zhenkun Maon behalf of the EVEREST-HP Study Group
The Lancet Infectious Diseases Vol 26(1):p101
Series（专题研讨会）
38
Prevention and Management of Infections in People who are Immunocompromised
免疫功能低下人群感染的预防和治疗
Innovation in active and passive immunisation of people who are immunocompromised: a call to action
免疫功能低下人群主动和被动免疫接种的创新：行动呼吁
Joshua A Hill,Jim Boonyaratanakornkit,Malgorzata Mikulska,Benjamin W Teh,William O Hahn,Ghady Haidar,Catherine Liu,Deepali Kumar,Michael G Ison,Natasha Halasa
The Lancet Infectious Diseases Vol 26(1):e16
39
Prevention and Management of Infections in People who are Immunocompromised
免疫功能低下人群感染的预防和治疗
Tackling antimicrobial resistance in people who are immunocompromised: leveraging diagnostic and antimicrobial stewardship
应对免疫功能低下人群的抗菌药物耐药性：利用诊断和抗菌药物管理
Catherine Liu,Emily A Rosen,Erica J Stohs,Hannah Imlay,Masayuki Nigo,Lee S Gottesdiener,Miranda So,Frank Tverdek,Sanjeet Dadwal,Carlota Gudiol,Michael J Satlin,Susan K Seo,Jason A Trubiano,Ritu Banerjee,Kimberly E Hanson,Lilian M Abbo
The Lancet Infectious Diseases Vol 26(1):e30
Review（综述）
40
Unveiling the incidences and trends of alveolar echinococcosis in Europe: a systematic review from the KNOW-PATH project
揭示欧洲肺泡棘球蚴病的发病率和趋势：来自KNOW-PATH项目的系统综述
Adriano Casulli,Bernadette Abela,Daniele Petrone,Barbara Šoba,Balázs Dezsényi,Jacek Karamon,Laurence Millon,Urmas Saarma,Daniela Antolová,François Chappuis,Severin Gloor,Marcel Stoeckle,Beat Müllhaupt,Relja Beck,Heimo Lagler,Felix Lötsch,Herbert Auer,Marie-Pierre Hayette,Libuše Kolářová,Sniedze Laivacuma,Mindaugas Šarkūnas,Vitalijus Sokolovas,Audronė Marcinkutė,Karin Troell,Ansgar Deibel,Pikka Jokelainen,Małgorzata Sulima,Dagny Krankowska,Stillhard Roman,Gaëtan-Romain Joliat,Nermin Halkic,Solange Bresson-Hadni,Joanna Halina Bednarek,Andrzej Załęski,Małgorzata Paul,Sheraz Yaqub,Mogens Jensenius,Joke van der Giessen,Laura Nabarro,Peter Chiodini,Florent Demonmerot,Jenny Knapp,Beate Grüner,Peter Kern,Lynn Peters,Federica Santolamazza,Azzurra Santoro
The Lancet Infectious Diseases Vol 26(1):e49
Personal View（个人观点）
41
Azithromycin mass drug administration: balancing survival benefits and risks in children
阿奇霉素大规模药物给药：平衡儿童生存益处与风险
Nubwa Medugu,Ian C Michelow,Claudette Poole,Stephen K Obaro
The Lancet Infectious Diseases Vol 26(1):e62
Clinical Picture（临床影像）
42
Unexpected finding in a 17-year-old female undergoing screening colonoscopy
17岁女性接受筛查结肠镜检查时的意外发现
Ziheng Calvin Xu,Ethan Tan,Mayur Garg
The Lancet Infectious Diseases Vol 26(1):e75
THE LANCET Infectious Diseases. Volume 26Number 2
柳叶刀传染病学 26卷 2期
https://www.thelancet.com/journals/laninf/issue/current
EDITORIAL(社论)
1
Call for letters
征稿启事
The Lancet Infectious Diseases
The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：p111
Comment（述评）
2
Long COVID is here to stay—even in children
长期新冠症状将持续存在——即使在儿童中亦是如此
Danilo Buonsenso
The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：p112
3
Beyond ritonavir-boosted nirmatrelvir: the case for ensitrelvir in COVID-19 treatment
利托那韦强化版奈玛特韦之外的选择：恩赛特韦在新冠肺炎治疗中的应用
Ming Hong Choi,Ivan Fan Ngai Hung
The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：p113
4
A new monoclonal in the arMAMentarium against malaria
抗疟“武器库”中的新型单克隆抗体
Freia-Raphaella Lorenz,Matthew B B McCall
The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：p115
5
Household transmission of mpox in Africa: limited in adults but more prevalent in children
非洲猴痘家庭传播情况：在成人中传播有限，但在儿童中更为普遍
Oriol Mitjà,Michael Marks
The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：p117
6
The lasting lessons of mpox: infection, vaccination, and immune memory
猴痘带来的持久教训：感染、疫苗接种和免疫记忆
Raianna Fantin,Camila H Coelho
The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：p118
7
Xpert-Ultra for diagnosing asymptomatic tuberculosis
Xpert-Ultra用于诊断无症状结核病
Xia Yu,Hairong Huang
The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：p120
8
The genomic surveillance gap: averting the antimicrobial resistance pandemic requires global equity and action
基因组监测的差距：避免抗菌药物耐药性大流行需要全球公平与行动
David M Aanensen,Iruka N Okeke,Pilar Donado-Godoy,Beverly Egyir,Ravikumar K Lingegowda,Sonia Siaon behalf of the NIHR Global Health Research Unit on Genomic Surveillance of AMR
The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：p122
Correspondence（读者来信）
9
Spillover in dengue trials
登革热试验中的溢出效应
Thomas A Smith,Samuel I Watson
The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：e77
10
Spillover in dengue trials – Author's reply
登革热试验中的溢出效应——作者回复
Fernando Abad-Franch
The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：e78
11
Updating the traditional voriconazole trough concentration range
传统的伏立康唑谷浓度范围更新
Rongqiang Liao,Xiaoyuan Zheng
The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：e79
12
Updating the traditional voriconazole trough concentration range – Authors' reply
传统的伏立康唑谷浓度范围更新——作者回复
Inderpaul Singh Sehgal,Ritesh Agarwal,Valliappan Muthu
The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：e80
13
Clinical course and neurological profile of Kyasanur Forest disease
基萨努尔森林病的临床病程和神经特征
Nitin Gupta,Tirlangi Praveen Kumar
The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：e82
Corrections（更正）
14
Correction to Lancet Infect Dis 2025; published online Oct 10. https://doi.org/10.1016/S1473-3099(25)00482-7
对《柳叶刀-传染病》2025年发表内容的更正；10月10日在线发表。https://doi.org/10.1016/S1473-3099(25)00482-7
The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：e83
15
Correction to Lancet Infect Dis 2025; published online Dec 1. https://doi.org/10.1016/S1473-3099(25)00681-4
对《柳叶刀-传染病》2025年发表内容的更正；12月1日在线发表。https://doi.org/10.1016/S1473-3099(25)00681-4
The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：e83
Newsdesk（新闻台）
16
Promising early data for sorfequiline
索氟维林早期数据令人鼓舞
Ed Holt
The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：e84
17
Highlights from ASTMH 2025
2025年美国热带医学与卫生学会年会亮点
Marco De Ambrogi
The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：e85
18
Brazil approves domestic single-shot dengue vaccine
巴西批准国产单剂登革热疫苗
Marcia Triunfol
The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：e86
19
CDC cuts to childhood vaccine recommendations
美国疾控中心削减儿童疫苗接种建议
Priya Venkatesan
The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：e87
20
WHO launches unified plan for coronaviruses
世界卫生组织启动冠状病毒统一计划
Talha Burki
The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：e88
21
Infectious disease surveillance update
传染病监测更新
Cahal McQuillan
The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：e89
22
Research in brief
研究简讯
Priya Venkatesan
The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：e90
Obituary（讣告）
23
Walter Dowdle
沃尔特·道德尔
Sanjeet Bagcchi
The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：p124
Profile（人物简介）
24
Katie Anders—improving global dengue control
凯蒂·安德斯——改善全球登革热防控
Tony Kirby
The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：p125
Media Watch（媒体观察）
Film（电影）
25
Eliminating Guinea worm
根除麦地那龙线虫
Sanjeet Bagcchi
The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：p126
Articles（论著）
26
Long COVID associated with SARS-CoV-2 reinfection among children and adolescents in the omicron era (RECOVER-EHR): a retrospective cohort study
奥密克戎时代儿童与青少年长期新冠症状与SARS-CoV-2再感染的关联（RECOVER-EHR）：一项回顾性队列研究
Bingyu Zhang,Qiong Wu,Ravi Jhaveri,Ting Zhou,Michael J Becich,Yuriy Bisyuk,Frank Blanceró,Elizabeth A Chrischilles,Cynthia H Chuang,Lindsay G Cowell,Daniel Fort,Carol R Horowitz,Susan Kim,Nathalia Ladino,David M Liebovitz,Mei Liu,Abu S M Mosa,Hayden T Schwenk,Srinivasan Suresh,Bradley W Taylor,David A Williams,Jeffrey S Morris,Christopher B Forrest,Yong Chenon behalf of the RECOVER Consortium
The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：p127
27
Antiviral efficacy of oral ensitrelvir versus oral ritonavir-boosted nirmatrelvir in COVID-19 (PLATCOV): an open-label, phase 2, randomised, controlled, adaptive trial
口服恩赛特韦与口服利托那韦强化版奈玛特韦在新冠肺炎治疗中的抗病毒疗效（PLATCOV）：一项开放标签、2期、随机、对照、适应性试验
William H K Schilling,Podjanee Jittamala,Phrutsamon Wongnak,James A Watson,Simon Boyd,Viravarn Luvira,Tanaya Siripoon,Thundon Ngamprasertchai,Elizabeth M Batty,Ellen Beer,Shivani Singh,Tanatchakorn Asawasriworanan,Timothy Seers,Koukeo Phommasone,Terry John Evans,Varaporn Kruabkontho,Thatsanun Ngernseng,Jaruwan Tubprasert,Mohammad Yazid Abdad,Wanassanan Madmanee,Jindarat Kouhathong,Kanokon Suwannasin,Watcharee Pagornrat,Tianrat Piteekan,Borimas Hanboonkunupakarn,Kittiyod Poovorawan,Manus Potaporn,Attasit Srisubat,Bootsakorn Loharjun,Kesinee Chotivanich,Mallika Imwong,Sasithon Pukrittayakamee,Arjen M Dondorp,Nicholas P J Day,Watcharapong Piyaphanee,Weerapong Phumratanaprapin,Nicholas J Whiteon behalf of the PLATCOV Collaborative Group
The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：p139
28
Cefiderocol versus standard therapy for hospital-acquired and health-care-associated Gram-negative bacterial bloodstream infection (the GAME CHANGER trial): an open-label, parallel-group, randomised trial
头孢地尔与标准疗法治疗医院获得性和医疗保健相关性革兰氏阴性菌血流感染（GAME CHANGER试验）：一项开放标签、平行分组、随机试验
David L Paterson,Helmi Sulaiman,Po-Yu Liu,Mark D Chatfield,Mesut Yilmaz,Zeti Norfidiyati Salmuna,Mohd Zulfakar Mazlan,Siriluck Anunnatsiri,Rujipas Sirijatuphat,Darunee Chotiprasitsakul,David C Lye,Jyoti Somani,Shirin Kalimuddin,Abdullah T Aslan,Visanu Thamlikitkul,Yi-Tzu Lee,Ya-Sung Yang,Yi-Tsung Lin,Wan Nurliyana Wan Ramli,Chien-Hao Tseng,Sophia Archuleta,Yvonne Fu Zi Chan,Brian M Forde,Hugh Wright,Adam G Stewart,Kay A Ramsay,Weiping Ling,Vicki Rossi,Tiffany M Harris-Brown,Patrick N A Harrison behalf of the GAME CHANGER Trial Investigators
The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：p148
29
Efficacy and safety of ascending doses of orodispersible ivermectin co-administered with albendazole for Trichuris trichiura infections in preschool-aged children in Tanzania: a 坦桑尼亚学龄前儿童感染毛首鞭形线虫时，递增剂量口服分散片伊维菌素与阿苯达唑联合用药的疗效和安全性：一项单盲、随机、对照、剂量递增、2期试验
single-blind, randomised, controlled, dose-ranging, phase 2 trial
Viviane P Sprecher,Annina Schnoz,Stefan Biendl,Halima S Hussein,Sarah O Najim,Mohammed N Ali,Ibrahim S Mohammed,Said M Ali,Jan Hattendorf,Jennifer Keiser
The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：p160
30
Human monoclonal antibody MAM01 for protection against malaria in adults in the USA: a first-in-human, phase 1, dose-escalation, double-blind, placebo-controlled, adaptive trial
人源单克隆抗体MAM01保护美国成年人免受疟疾侵害：一项首次人体、1期、剂量递增、双盲、安慰剂对照、适应性试验
Kirsten E Lyke,Andrea A Berry,Matthew B Laurens,Jennifer Winkler,Sudhaunshu Joshi,Abra Rachida Koudjra,Lauryn Butler,Peter F Billingsley,Tales Pascini,Asha Patil,B Kim Lee Sim,Grace Fitzgerald,Julie Riegel,Kayla Andrews,Micha Levi,Aparna B Anderson,Charles D Wells,Hong Liu,James Huleatt,R Scott Miller
The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：p170
31
Characterising household transmission dynamics of clade Ib mpox in Burundi: a prospective cohort study
布隆迪Ib分支猴痘家庭传播动力学特征：一项前瞻性队列研究
Raoul Kamadjeu,Ferdinand Nsengimana,Manassé Nimpagaritse,Edna Moturi,Eric Kezakarayagwa,Rose Nkiko,Jonas Ngendakumana,Rémy Nimubona,Liliane Nkengurutse,Hamady Ba,Dionis Nizigiyimana,Paul Ngwakum,Mame Selbee Diouf,France Bégin,Joseph Nyandwi,Douglas James Noble
The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：p182
32
Long-term consequences of monkeypox virus infection or modified vaccinia virus Ankara vaccination in Belgium (MPX-COHORT and POQS-FU-PLUS): a 24-month prospective and retrospective cohort study
比利时猴痘病毒感染或改良痘苗病毒安卡拉株疫苗接种的长期后果（MPX-COHORT和POQS-FU-PLUS）：一项为期24个月的前瞻性和回顾性队列研究
Christophe Van Dijck,Nicole Berens-Riha,Luca M Zaeck,Cécile Kremer,Jacob Verschueren,Jasmine Coppens,Fien Vanroye,Elisabeth Willems,Evi Bosman,Natalie De Cock,Bart Smekens,Leen Vandenhove,Odin Goovaerts,Anke Van Hul,Janne Wouters,Bart K M Jacobs,Stefanie Bracke,Matilde Hens,Isabel Brosius,Elise De Vos,Eugene Bangwen,Sarah Houben,Achilleas Tsoumanis,Pedro Henrique Lopes Ferreira Dantas,Jojanneke Rutgers,Amber Lipman,Koen Wijnans,Patrick Soentjens,Emmanuel Bottieau,Chris Kenyon,Johan van Griensven,Thijs Reyniers,Niels Horst,Kevin K Ariën,Marjan Van Esbroeck,Andrea Torneri,Koen Vercauteren,Wim Adriaensen,Rory D de Vries,Joachim Mariën,Laurens Liesenborghs
The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：p190
33
Long-term risk of tuberculosis among individuals with Xpert Ultra trace screening results in Uganda: a longitudinal follow-up study
乌干达Xpert Ultra微量筛查结果阳性个体患结核病的长期风险：一项纵向随访研究
Joowhan Sung,Mariam Nantale,Annet Nalutaaya,Patrick Biché,James Mukiibi,Joab Akampurira,Rogers Kiyonga,Francis Kayondo,Michael Mukiibi,Caitlin Visek,Caleb E Kamoga,David W Dowdy,Achilles Katamba,Emily A Kendall
The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：p203
Review（综述）
34
Invasive group A streptococcal infections: lessons learned from the 2022–23 upsurge
侵袭性A组链球菌感染：从2022-23年激增中吸取的教训
Alix Flamant,Alicia Demirjian,Theresa Lamagni,Julie Toubiana,Pierre R Smeesters,Jérémie F Cohen
The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：e91
35
A clinical practice guideline for tuberculous meningitis
结核性脑膜炎临床实践指南
Joseph Donovan,Fiona V Cresswell,Elizabeth W Tucker,Angharad G Davis,Ursula K Rohlwink,Julie Huynh,Regan Solomons,James A Seddon,Nathan C Bahr,Arjan van Laarhoven,Suzanne T Anderson,Sanjay K Jain,Felicia C Chow,Sophie Pattison,James E Scriven,Gabriela Singh,Rob E Aarnoutse,Jan-Willem C Alffenaar,Sofiati Dian,Abi Manesh,Robin Basu Roy,Varinder Singh,Ronald van Toorn,Caryn M Upton,Reinout van Crevel,Kelly E Dooley,Diana Gibb,David Meya,Robert J Wilkinson,Ewelina Rogozińska,Usha K Misra,Anthony Figaji,Guy E Thwaites
The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：e96
36
Towards shorter therapy for candidaemia: defining uncomplicated candidaemia in adults
缩短念珠菌血症疗程：界定成人非复杂性念珠菌血症
Ilana Reinhold,Susanne Picardi,Blasius Liss,Danila Seidel,Jannik Stemler,Philipp Koehler,Tamara Ruegamer,Rosanne Sprute,Oliver A Cornely
The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：e112
Personal View（个人观点）
37
A transformation in cholera surveillance
霍乱监测的变革
Amanda K Debes,Erin T Baumgartner,Kendra N Williams,David A Sack
The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：e124
Clinical Picture（临床图像）
38
Paediatric ocular toxocariasis with relentless progression despite negative metagenomic testing
尽管宏基因组检测呈阴性，但儿科眼弓蛔虫病仍持续进展
Diya Shah,Shiama Balendra,Harry Petrushkin,Anamika Patel
The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：e130
THE LANCET Infectious Diseases. Volume 26Number 3
柳叶刀传染病学 26卷 3期
https://www.thelancet.com/journals/laninf/issue/current
EDITORIAL（社论）
1
Promises and challenges of AI in infectious diseases
人工智能在传染病领域的承诺与挑战
The Lancet Infectious Diseases
The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：p213
COMMENT（述评）
2
More real-world evidence for RSV vaccines in the global community
全球范围社区呼吸道合胞病毒（RSV）疫苗的更广泛的现实证据
Kristina L Bajema,Wesley H Self
The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：p214
3
Rapid diagnostic antigen tests for mpox and the need for decentralised testing—not quite there yet
猴痘快速诊断抗原检测及分散检测的必要性——尚待完善
Daniel Mukadi-Bamuleka,Kevin K Ariën
The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：p215
4
Solving the data bottleneck for artificial intelligence in infectious diseases
解决传染病人工智能领域的数据瓶颈问题
Cesar de la Fuente-Nunez
The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：p217
5
Artificial intelligence and One Health: potential for spillover prediction?
人工智能与“同一健康”理念：能否预测病原体外溢？
Marion Koopmans,Istvan Csabai,Daniel Remondini,Emma Snary,Frank Aarestrup
The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：p219
6
Artificial intelligence in the development of vaccines for infectious diseases
人工智能在传染病疫苗研发中的应用
Steve Black,Shabir A Madhi,Rino Rappuoli
The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：p221
7
Peer review at The Lancet Infectious Diseases in 2025
2025年《柳叶刀-传染病学》期刊专家评审
Ursula Hofer
The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：p223
8
Thank you to The Lancet Infectious Diseases statistical and peer reviewers in 2025
感谢2025年《柳叶刀-传染病学》期刊的统计学及评审专家
The Lancet Infectious Diseases Editors
The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：e132
CORRESPONDENCE（读者来信）
9
Methodological considerations in the attribution of long COVID to first or second infection
首次或二次感染导致长期新冠症状的方法学考量
Sara Carazo,Danuta M Skowronski,Manale Ouakki,Gaston De Serres
The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：e139
10
Methodological considerations in the attribution of long COVID to first or second infection – Authors' reply
首次或二次感染导致长期新冠症状的方法学考量——作者回复
Bingyu Zhang,Qiong Wu,Ravi Jhaveri,Christopher B Forrest,Yong Chen
The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：e141
11
Humoral immunity after LP.8.1 monovalent vaccines against a broad range of SARS-CoV-2 variants including XEC, LP.8.1, NB.1.8.1, XFG, and BA.3.2
LP.8.1单价疫苗针对包括XEC、LP.8.1、NB.1.8.1、XFG和BA.3.2在内的多种SARS-CoV-2变异株的体液免疫应答
Yu Kaku,Mizuka Fujiwara,Keiya Uriu,Maximilian Stanley Yo,Shusuke Kawakubo,Jumpei Ito,Naoya Itoh,Yoshifumi Uwamino,Fumitake Saito,Hironori Satoh,The Genotype to Phenotype Japan (G2P-Japan) Consortium,Kei Sato
The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：e142
12
Precision diagnostics for MBLs: the true game changer in treating antimicrobial resistance
金属β-内酰胺酶精准诊断：治疗抗菌药物耐药性的真正变革者
Brenda A Warecki,María F Mojica,Alejandro J Vila,Robert A Bonomo
The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：e144
13
Precision diagnostics for MBLs: the true game changer in treating antimicrobial resistance – Authors' reply
金属β-内酰胺酶精准诊断：治疗抗菌药物耐药性的真正变革者——作者回复
David L Paterson,Abdullah T Aslan,Patrick N A Harris
The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：e145
CORRECTIONS（更正）
14
Correction to Lancet Infect Dis 2025; published online Dec 9. https://doi.org/10.1016/S1473-3099(25)00659-0
《柳叶刀-传染病学》2025年发表文章勘误；在线发表于12月9日。https://doi.org/10.1016/S1473-3099(25)00659-0
The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：e146
15
Correction to Lancet Infectious Diseases 2026; published online Jan 20. https://doi.org/10.1016/S1473-3099(25)00773-X
《柳叶刀-传染病学》2026年发表文章勘误；在线发表于1月20日。https://doi.org/10.1016/S1473-3099(25)00773-X
The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：e146
NEWSDESK（新闻台）
16
Rabies an increasing threat in Ukraine
乌克兰狂犬病威胁日益加剧
Ed Holt
The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：e147
17
People needing trachoma interventions at record low
需要沙眼干预措施的人数创历史新低
Timothy Jesudason
The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：e148
18
Uneven STI response in EU/EEA countries
欧盟/欧洲经济区国家性传播感染应对措施不均衡
Sanjeet Bagcchi
The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：e149
19
Controversial HBV vaccine trial in Guinea-Bissau halted
几内亚比绍有争议的乙型肝炎病毒疫苗试验被叫停
Talha Burki
The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：e150
20
Research in brief
研究简讯
Priya Venkatesan
The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：e151
OBITUARY（讣告）
21
Ivan Hirsch
伊万·赫希
Sanjeet Bagcchi
The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：p224
PROFILE（人物介绍）
22
Reem Abu Shomar— championing water safety in Gaza
里姆·阿布·舒马尔——加沙地带水安全倡导者
Tony Kirby
The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：p225
MEDIA WATCH（媒体观察）
Book（书籍）
23
A prescription for public health literacy
提升公众健康素养的良方
Vijay Shankar Balakrishnan
The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：p226
Book（书籍）
24
Imagining the inevitable
想象不可避免之事
Cahal McQuillan
The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：p227
Film（电影）
25
Women's autonomy, safe sex and HIV prevention
女性自主权、安全性行为与艾滋病预防
Sanjeet Bagcchi
The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：p228
ARTICLES（论著）
26
Vaccine effectiveness of a bivalent respiratory syncytial virus (RSV) pre-F vaccine against RSV-associated hospital admission among adults aged 75–79 years in England: a multicentre, test-negative, case–control study
英国75-79岁成年人中双价呼吸道合胞病毒（RSV）预融合F蛋白疫苗对RSV相关住院的有效性：一项多中心、检测阴性、病例对照研究
Rebecca Symes,Heather J Whitaker,Shazaad Ahmad,David Arnold,Suryabrata Banerjee,Cariad M Evans,Robin Gore,Jennifer Hart,Katy Heaney,Onn Min Kon,Anne Melhuish,Munira Ortale Zogaib,Emanuela Pelosi,Najib M Rahman,Gerrit Woltmann,Tricia McKeever,Maria Zambon,Conall H Watson,Wei Shen Lim,Jamie Lopez Bernalon behalf of the HARISS network collaborators
The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：p229
27
Oral itraconazole versus oral voriconazole for treatment-naive patients with chronic pulmonary aspergillosis in India (VICTOR-CPA trial): a single-centre, open-label, randomised, controlled, superiority trial
印度治疗初治慢性肺曲霉病患者口服伊曲康唑与口服伏立康唑的对比研究（VICTOR-CPA试验）：一项单中心、开放标签、随机、对照、优效性试验
Inderpaul Singh Sehgal,Ritesh Agarwal,Sahajal Dhooria,Kuruswamy Thurai Prasad,Valliappan Muthu,Ashutosh Nath Aggarwal,Shivaprakash M Rudramurthy,Mandeep Garg,Arunaloke Chakrabarti
The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：p239
28
Accounting for non-adherence to assigned antibiotic treatment duration for bloodstream infection (BALANCE): a post-hoc analysis of a randomised clinical trial
血流感染抗生素治疗疗程依从性考量（BALANCE）：一项随机临床试验的事后分析
Sean W X Ong,Ruxandra Pinto,Robert K Mahar,Asgar Rishu,Joshua S Davis,Robert A Fowler,Steven Y C Tong,Nick Danemanfor the BALANCE trial consortium
The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：p250
29
Field evaluation of a rapid antigen test for mpox in the Democratic Republic of the Congo and Uganda: a multicentre, prospective, diagnostic accuracy study
刚果民主共和国和乌干达猴痘快速抗原检测的现场评估：一项多中心、前瞻性、诊断准确性研究
Barnabas Bakamutumaho,David Lupande Mwenebitu,Winters Muttamba,Ingrid Ampeire,Henry Kyobe Bosa,Esto Bahizire,Bertin Casinga Bisimwa,Andrew Obuku,Misaki Wayengera,Alison Sandeman,Matthew T G Holden,Patrick D M C Katoto,Bruce Kirenga,Deborah A Williamson,Wilber Sabiiti
The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：p260
30
Complications and mortality of typhoid fever: an updated global systematic review and meta-analysis
伤寒热的并发症与死亡率：一项更新的全球系统综述与荟萃分析
Shruti Murthy,Nienke N Hagedoorn,Suzanne Faigan,Meera D Rathan,Christian S Marchello,John A Crump
The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：p270
31
Global, regional, and national burden of Chagas disease, 1990–2023: a systematic analysis for the Global Burden of Disease Study 2023
1990-2023年全球、区域和国家层面查加斯病负担：2023年全球疾病负担研究的系统分析
GBD 2023 Chagas Disease and RAISE Study Collaborators
The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：p284
32
Safety, tolerability, and immunogenicity of the ChAdOx1 RVF vaccine against Rift Valley fever among healthy adults in Uganda: a single-centre, single-blind, randomised, placebo-controlled, dose-escalation, phase 1 trial
乌干达健康成年人中ChAdOx1裂谷热疫苗的安全性、耐受性和免疫原性：一项单中心、单盲、随机、安慰剂对照、剂量递增的1期试验
Zacchaeus Anywaine,Jennifer Serwanga,Abu-Baker Mustapher Ggayi,Andrew Max Abaasa,Daniel Wright,Ben Gombe,Peter Ejou,Tamara Namata,Antony Kigozi,Naboth Tukamwesiga,Vincent Basajja,Violet Ankunda,Dora Jocelyn Mulondo,Florence Nambaziira,Ayoub Kakande,Wilson Kakeeto,Phiona Nabaggala,Daniel Jenkin,Alison Lawrie,Pedro Folegatti,Nguyen Tran,Christian Hansen,Alison M Elliott,Adrian V S Hill,George M Warimwe,Pontiano Kaleebu
The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：p302
33
Immunogenicity and safety of an 18-month booster dose of the VLA15 Lyme borreliosis vaccine candidate after primary immunisation in children, adolescents, and adults in the USA: a randomised, observer-blind, placebo-controlled, phase 2 trial
美国儿童、青少年和成人基础免疫后18个月VLA15莱姆病疫苗候选物的加强免疫接种的免疫原性和安全性：一项随机、观察者盲法、安慰剂对照的2期试验
Laura Wagner,Michaela Obersriebnig,Romana Hochreiter,Vera Kadlecek,Julian Larcher-Senn,Lisa Hegele,Jason D Maguire,Timothy Murphy,Ulla Derhaschnig,Nicole Bézay,Juan Carlos Jaramillo,Susanne Eder-Lingelbach,Marc Messier
The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：p314
SERIES（研讨会）
Artificial Intelligence and Infectious Diseases
人工智能与传染病
34
Artificial intelligence and infectious diseases: an evidence-driven conceptual framework for research, public health, and clinical practice
人工智能与传染病：基于证据的研究、公共卫生和临床实践概念框架
Anna Odone,Chiara Barbati,Silvia Amadasi,Tanja Schultz,David B Resnik
The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：e152
35
Artificial intelligence and infectious disease diagnostics: state of the art and future perspectives
人工智能与传染病诊断：现状与未来展望
Luca Miglietta,Timothy M Rawson,Ronald Galiwango,Alex Tasker,Damien K Ming,Darlington Akogo,Cecilia Ferreyra,Eric O Aboagye,N Claire Gordon,Carolina Garcia-Vidal,Jesus Rodriguez-Manzano,Alison H Holmes
The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：e168
36
Artificial intelligence and infectious diseases: tackling antimicrobial resistance, from personalised care to antibiotic discovery
人工智能与传染病：应对抗菌药物耐药性，从个性化治疗到抗生素发现
Alex Howard,Nada Reza,Peter L Green,Mo Yin,Erin Duffy,Henry C Mwandumba,Alessandro Gerada,William Hope
The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：e181
REVIEW（综述）
37
Community-acquired respiratory virus infections in patients with haematological malignancies or undergoing haematopoietic cell transplantation: updated recommendations from the 10th European Conference on Infections in Leukaemia
血液系统恶性肿瘤患者或接受造血细胞移植患者社区获得性呼吸道病毒感染：第10届欧洲白血病感染会议更新建议
Marie von Lilienfeld-Toal,Fareed Khawaja,Francesca Compagno,Christine Robin,José-Luis Piñana,Simone Cesaro,Hermann Einsele,Per Ljungman,David Navarro,Michael Boeckh,Roy F Chemaly,Hans H Hirsch
The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：e193
CLINICAL PICTURE（临床图像）
38
Mycoplasma hominis toe osteomyelitis: a rare and unusual bone infection
人型支原体足趾骨髓炎：一种罕见且不寻常的骨感染
Cheryl Keel,Pauleen McSherry,Rebecca Thombre,Sendurann Nadarajah,Rediat Tewolde,Owen B
Spiller,Baharak Afshar
The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：e207
THE LANCET Infectious Diseases. Volume 26Number 4
柳叶刀传染病学 26卷 4期
https://www.thelancet.com/journals/laninf/issue/current
EDITORIAL(社论)
1
GoGoVax dispels hopes for gonorrhoea vaccination
GoGoVax让淋病疫苗的希望破灭
The Lancet Infectious Diseases
The Lancet Infectious Diseases. Apr 2026，Vol 26(4)：p329
COMMENT（述评）
2
Do the benefits of universal screening outweigh the harms?
全民筛查的益处是否大于害处？
Alanna N Gillespie,Emma Webb,Valerie Sung
The Lancet Infectious Diseases. Apr 2026，Vol 26(4)：p330
3
Chikungunya in Brazil: vaccination strategies informed by mathematical modelling
巴西基孔肯雅热：基于数学建模的疫苗接种策略
José Lourenço,Marta Giovanetti
The Lancet Infectious Diseases. Apr 2026，Vol 26(4)：p331
4
Chikungunya adolescent vaccination and the distinct risk–benefit landscapes
青少年接种基孔肯雅热疫苗及独特的风险-获益情况
Ernesto T A Marques,Simon Barratt-Boyes
The Lancet Infectious Diseases. Apr 2026，Vol 26(4)：p333
5
Circulation of clade Ib mpox outside of Africa—are we prepared?
非洲以外地区Ib分支猴痘的传播——我们准备好了吗？
Seth D Judson,Claude Kwe Yinda,Franziska K Kaiser,Daniel S Chertow,Emmie de Wit,James O Lloyd-Smith,Vincent J Munster
The Lancet Infectious Diseases. Apr 2026，Vol 26(4)：p334
6
I worked at WHO: the USA leaving will not make America healthier
我曾在世卫组织工作：美国退出不会让美国更健康
Krutika Kuppalli
The Lancet Infectious Diseases. Apr 2026，Vol 26(4)：p336
CORRESPONDENCE（读者来信）
7
Maternal views on RSV vaccination in the UK's second season
英国第二季呼吸道合胞病毒疫苗接种的产妇观点
Shaun O'Hagan,Steve Cunningham,Simon B Drysdale,Helen E Groves,Samantha Hunt,Dalia Iskander,Xinxue Liu,Mark D Lyttle,Chengetai D Mpamhanga,Thomas Waterfield,Thomas C Williams,Robin Marlow,Damian Rolandon behalf of the PERUKI & BronchStart/Stop Collaboration
The Lancet Infectious Diseases. Apr 2026，Vol 26(4)：e209
8
Overcoming immune imprinting with the COVID-19 LP.8.1 mRNA boosters
利用COVID-19 LP.8.1 mRNA加强针克服免疫印记
Ninaad Lasrado,Annika Rössler,Katherine Molloy,Isabella McConnell,Ritobhas Bhowmik,Francisco Armando Granados-Contreras,Jessica Wu,Alejandra Waller-Pulido,Samuel J Nangle,Erica Borducchi,Ai-ris Y Collier,Dan H Barouch
The Lancet Infectious Diseases. Apr 2026，Vol 26(4)：e212
CORRECTIONS（更正）
9
Correction to Lancet Infect Dis 2025; published online Nov 27.
https://doi.org/10.1016/S1473-3099(25)00605-X
《柳叶刀-传染病学》2025年刊载内容更正；在线发布于11月27日
The Lancet Infectious Diseases. Apr 2026，Vol 26(4)：e214
10
Correction to Lancet Infect Dis 2026; 26: 343–61
《柳叶刀-传染病学》2026年刊载内容更正；26卷：343-61页
The Lancet Infectious Diseases. Apr 2026，Vol 26(4)：e214
11
Correction to Lancet Infect Dis 2026; published online Jan 23. https://doi.org/10.1016/S1473-3099(25)00730-3
《柳叶刀-传染病学》2026年刊载内容更正；在线发布于1月23日
The Lancet Infectious Diseases. Apr 2026，Vol 26(4)：e214
12
Correction to Lancet Infect Dis 2026; published online Jan 28. https://doi.org/10.1016/S1473-3099(25)00747-9
《柳叶刀-传染病学》2026年刊载内容更正；在线发布于1月28日
The Lancet Infectious Diseases. Apr 2026，Vol 26(4)：e214
NEWSDESK（新闻台）
13
UK loses measles elimination status as cases rise
随着病例增加，英国失去麻疹消除地位
Priya Venkatesan
The Lancet Infectious Diseases. Apr 2026，Vol 26(4)：e215
14
Brazil launches implementation study of lenacapavir
巴西启动来那卡帕韦实施研究
Tony Kirby
The Lancet Infectious Diseases. Apr 2026，Vol 26(4)：e216
15
Clade Ib mpox in southwest Indian Ocean islands
西南印度洋岛屿出现Ib分支猴痘
Esther Nakkazi
The Lancet Infectious Diseases. Apr 2026，Vol 26(4)：e217
16
EMA approves combined COVID-19 and flu mRNA vaccine
欧洲药品管理局批准COVID-19和流感联合mRNA疫苗
Talha Burki
The Lancet Infectious Diseases. Apr 2026，Vol 26(4)：e218
17
Research in brief
研究简讯
Priya Venkatesan
The Lancet Infectious Diseases. Apr 2026，Vol 26(4)：e219
OBITUARY（讣告）
18
Nicholas John White
尼古拉斯·约翰·怀特
Sanjeet Bagcchi
The Lancet Infectious Diseases. Apr 2026，Vol 26(4)：p339
PROFILE（人物简介）
19
Katharina Kranzer—led by curiosity, committed to capacity
卡塔琳娜·克兰泽——受好奇心驱使，致力于提升能力
Tony Kirby
The Lancet Infectious Diseases. Apr 2026，Vol 26(4)：p340
MEDIA WATCH（媒体观察）
Film（电影）
20
Leishmaniasis: a story of two continents
利什曼病：两个大陆的故事
Vijay Shankar Balakrishnan
The Lancet Infectious Diseases. Apr 2026，Vol 26(4)：p341
Book（书籍）
21
Finding your voice in a world of uncertainty
在不确定的世界中找到自己的声音
Carrie Fielden
The Lancet Infectious Diseases. Apr 2026，Vol 26(4)：p342
ARTICLES（论著）
22
Global burden of lower respiratory infections and aetiologies, 1990–2023: a systematic analysis for the Global Burden of Disease Study 2023
1990-2023年下呼吸道感染的全球负担及病因：2023年全球疾病负担研究的系统分析
GBD 2023 Lower Respiratory Infections and Antimicrobial Resistance Collaborators
GBD 2023下呼吸道感染和抗菌素耐药性协作组
The Lancet Infectious Diseases. Apr 2026，Vol 26(4)：p343
23
Effectiveness of the maternal RSVpreF vaccine against severe disease in infants in Scotland, UK: a national, population-based case–control study and cohort analysis
英国苏格兰地区母体RSVpreF疫苗对婴儿严重疾病的保护效果：一项全国性、基于人群的病例对照研究和队列分析
Isobel McLachlan,Chris Robertson,Kirsty E Morrison,Ross McQueenie,Safraj Shahul Hameed,Cheryl Gibbons,Rachael Wood,Rachel Merrick,Louisa Pollock,Antonia Ho,Ting Shi,Thomas C Williams,Sir Aziz Sheikh,Jim McMenamin,Sam Ghebrehewet,Kimberly Marsh
The Lancet Infectious Diseases. Apr 2026，Vol 26(4)：p362
24
Post-COVID-19 resurgence of Mycoplasma pneumoniae infections in French children (ORIGAMI): a retrospective and prospective multicentre cohort study
法国儿童COVID-19后支原体肺炎感染的复现（ORIGAMI）：一项回顾性和前瞻性多中心队列研究
Anaïs Chosidow,Zoha Maakaroun-Vermesse,Vichita Ok,Cécile Delecroix,Pascal Le Roux,Marie-Aliette Dommergues,Justine de Larminat,Eric Jeziorski,Pauline Ronjat,Léa Jaume,Anne Welfringer-Morin,Cécile Bébéar,Maud Gits-Muselli,Delphine Viriot,Charles-Joris Roux,Stéphane Bechet,Anne-Sophie Romain,Mathie Lorrot,Robert Cohen,Corinne Levy,Jérémie F Cohenon behalf of the ORIGAMI Study Group
The Lancet Infectious Diseases. Apr 2026，Vol 26(4)：p374
25
Lessons derived from a 3-year congenital cytomegalovirus screening programme in Israel: a prospective population-based cohort study
以色列先天性巨细胞病毒筛查项目的3年经验教训：一项前瞻性基于人群的队列研究
Smadar Eventov Friedman,Noa Ofek Shlomai,Esther Oiknine-Djian,Tal Sido,Oren Gordon,Sraya Greenberger,Hadar Horowitz,Lior Merav,Stav David Mehaber,Orit Caplan,Miriam Geal-Dor,Natalia Simanovsky,Diana Averbuch,Colin Kunzweiler,Yosefa Hefter,John Diaz-Decaro,Ora Paltiel,Moran Yassour,Dana G Wolf
The Lancet Infectious Diseases. Apr 2026，Vol 26(4)：p384
26
Comparison of the performance and costs of testing algorithms using rapid diagnostic tests for detection and treatment of syphilis among pregnant individuals and men who have sex with men: a modelling study
使用快速诊断检测方法对孕妇和男男性行为者进行梅毒检测和治疗的不同检测算法的性能和成本比较：一项建模研究
Ying Zhang,Eric P F Chow,Lei Zhang,Christopher K Fairley,Jason J Ong
The Lancet Infectious Diseases. Apr 2026，Vol 26(4)：p394
27
The epidemiology of chikungunya virus in Brazil and the potential impact of vaccines: a mathematical modelling study
巴西基孔肯雅热病毒的流行病学及疫苗的潜在影响：一项数学建模研究
Oscar Cortes-Azuero,Megan O'Driscoll,Gabriel Ribeiro dos Santos,Ronaldo de Jesus,Shirlene T S de Lima,Danny Scarponi,Christinah Mukandavire,Arminder Deol,Moritz U G Kraemer,William M de Souza,Henrik Salje
The Lancet Infectious Diseases. Apr 2026，Vol 26(4)：p406
28
Safety and immunogenicity of a live-attenuated chikungunya virus vaccine in adolescents: final results from a 12-month, double-blind, randomised, placebo-controlled, phase 3 trial in endemic areas of Brazil
青少年接种减毒活基孔肯雅热病毒疫苗的安全性和免疫原性：巴西流行地区一项为期12个月、双盲、随机、安慰剂对照的3期试验最终结果
Vera Buerger,Andrea Pfeiffer,Petra Schoengrundner,Jutta Seebacher,Romana Hochreiter,Karin Kosulin,Oliver Zoihsl,Petronela Weisova,Robert Mader,Ana Paula Loch,Eolo Morandi Jr,Mauricio Lacerda Nogueira,Carlos Alexandre Antunes de Brito,Julio Croda,Mauro Martins Teixeira,Ivo Castelo-Branco Coelho,Ricardo Gurgel,Allex Jardim da Fonseca,Marcus Vinícius Guimarães de Lacerda,Edson Duarte Moreira Jr,Ana Paula Rocha Veiga,Susanne Eder-Lingelbach,Juan Carlos Jaramillo
The Lancet Infectious Diseases. Apr 2026，Vol 26(4)：p417
29
National burden of and optimal vaccine policy for Japanese encephalitis virus in Bangladesh: a seroprevalence and modelling study
孟加拉国日本脑炎病毒的全国负担及最佳疫苗接种政策：一项血清流行率和建模研究
Mariana Perez Duque,Kishor K Paul,Rebeca Sultana,Gabriel Ribeiro dos Santos,Megan O'Driscoll,Abu M Naser,Mahmudur Rahman,Mohammad Shafiul Alam,Hasan M Al-Amin,Mohammed Z Rahman,Mohammad E Hossain,Repon C Paul,Elias Krainski,Stephen P Luby,Simon Cauchemez,Jessica Vanhomwegen,Emily S Gurley,Henrik Salje
The Lancet Infectious Diseases. Apr 2026，Vol 26(4)：p429
REVIEW（综述）
30
Autoantibodies in long COVID: a systematic review
长新冠中的自身抗体：一项系统综述
Fabian Wilhelm,Janne Cadamuro,Sylvia Mink
The Lancet Infectious Diseases. Apr 2026，Vol 26(4)：e220
31
Core outcome measurement set for clinical trials in dengue: an international Delphi consensus study (DEN-CORE)
登革热临床试验核心结局测量指标集：一项国际德尔菲共识研究（DEN-CORE）
Sophie Yacoub,Anastasia Demidova,Xin Hui S Chan,Ali Ajam,Dina Baimukhambetova,Andreij Horn,Evgeniia Kakotkina,Mark Kosenko,Aigun Mursalova,Jennifer Ilo Van Nuil,Chi Le Phuong,Lin Xiao,Sudeep Adhikari,Juan David Alzate Alvarez,Kathryn B Anderson,Panisadee Avirutnan,Stephanie Buchholz,Richa Chandra,Aileen Y Chang,Ho Quang Chanh,Mónika Patricia Consuegra Rodríguez,Vanessa Daniel,Janet V Diaz,Claudia Figueiredo-Mello,Rosa Margarita Gelvez-Ramírez,Tran Bang Huyen,Evelyne Kestelyn,Phung Khanh Lam,Stije J Leopold,Ruobing Li,Tran Luu,David Chien Boon Lye,Angela McBride,Isabelle Meyer-Andrieux,Nathaniel J Moorman,Nguyet Minh Nguyen,Sharifah Faridah Syed Omar,Hang Cheng Ong,Eng Eong Ooi,Ekaterina Pazukhina,Sarah L Pett,Diego Bastos Porto,Giri S Rajahram,Marc Rogers,Elsa Rojas,James Rosen,Jamie Rylance,William H K Schilling,Andre M Siqueira,Peter Sjö,Alfonso Sucerquia-Hernandez,Dong Thi Hoai Tam,Mauro Martins Teixeira,Andreas Tietz,Huynh Trung Trieu,Annalise Unsworth,Luis Villar,Adam Tully Waickman,James A Watson,Bridget A Wills,Po Ying Chia,Patricia Brasil,Thomas Jaenisch,Lucy Lum,Gathsaurie Neelika Malavige,Steven McGloughlin,Bharath Kumar Tirupakuzhi Vijayaraghavan,Laura Merson,Daniel Munblitthe DEN-CORE Study Group
The Lancet Infectious Diseases. Apr 2026，Vol 26(4)：e231
PERSONAL VIEW（个人观点）
32
Breaking the under-reporting cycle for zoonotic diseases in low-income and middle-income countries through national-level integration of community-based surveillance and response: insights from Cameroon, Chad, Côte d’Ivoire, and Mali
通过国家层面整合社区监测和响应，打破低收入和中等收入国家人畜共患病报告不足的循环：来自喀麦隆、乍得、科特迪瓦和马里的见解
Katherine E L Worsley-Tonks,Mahamat Fayiz Abakar,Zanan Coulibaly,Marie Paulette Deya-Yang,Linda Esso,Jean Marc Kameni Feussom,Vessaly Kallo,Zakaria Keita,Monique Lechenne,Magloire Tchamba Kombou,Inès Emah Manda,Christiane Mangou,Stephanie Mauti,Aime Gilert Mbonda Noula,Rodrigue Poueme Namegni,Perrine Parize,Mathurin Cyrille Tejiokem,Isaac Tiembre,Abdallah Traoré,Jakob Zinsstag,Hervé Bourhy
The Lancet Infectious Diseases. Apr 2026，Vol 26(4)：e245
GRAND ROUND（大查房）
33
Paediatric case of invasive group A streptococcal necrotising myositis: diagnostic challenges and lessons learned
儿童侵袭性A组链球菌坏死性肌炎病例：诊断挑战和经验教训
Suraya Yusuf,Michael James Carter,Jenny Woodruff,Peter Kalu,Justin Conrad Rosen Wormald,Claire Sethu
The Lancet Infectious Diseases. Apr 2026，Vol 26(4)：e259
CLINICAL PICTURE（临床图像）
34
Bullous haemorrhagic cellulitis caused by Escherichia coli in a patient with cirrhosis
肝硬化患者由大肠杆菌引起的大疱性出血性蜂窝织炎
Irene Rivera-Ruiz,Paloma Elma Alañón-Martínez,Elisa Vidal-Verdú
The Lancet Infectious Diseases. Apr 2026，Vol 26(4)：e268
2026-03-05
THE LANCET Infectious Diseases. Volume 26Number 1
柳叶刀传染病学 26卷 1期
https://www.thelancet.com/journals/laninf/issue/current
EDITORIAL(社论)
1
Urgent need for infection prevention and control in prisons
监狱中感染预防和控制的迫切需求
The Lancet Infectious Diseases
The Lancet Infectious Diseases Vol 26(1):p1
COMMENT（述评）
2
Now is the time to integrate serology into routine infectious disease surveillance
现在是时候将血清学纳入常规传染病监测了
Simon Cauchemez
The Lancet Infectious Diseases Vol 26(1):p2
3
Reassessing sotrovimab's role in COVID-19: insights and implications
重新评估索托维单抗在新冠肺炎治疗中的作用：见解与启示
Daniele Focosi,Fabrizio Maggi
The Lancet Infectious Diseases Vol 26(1):p3
4
Shaping opportunities for future clinical trials in tuberculosis
为未来结核病临床试验创造机会
Ivan Noreña,Beno Mbeya,Joanitah Nalunjogi,Ombeni Chimbe,Norbert Heinrich
The Lancet Infectious Diseases Vol 26(1):p5
5
Diversifying antimalarial treatment for uncomplicated Plasmodium falciparum malaria in Uganda
乌干达针对无并发症恶性疟原虫疟疾的抗疟治疗多样化
Arjen M Dondorp
The Lancet Infectious Diseases Vol 26(1):p6
6
A safe start for PfSPZ Vaccine, but efficacy in children remains elusive
PfSPZ疫苗安全起步，但在儿童中的疗效仍难以捉摸
Nicholas Aderinto,Temitomi Jane Oyedele
The Lancet Infectious Diseases Vol 26(1):p8
7
Rifasutenizol-based triple therapy for Helicobacter pylori infection
以利法苏替尼唑为基础的三联疗法治疗幽门螺杆菌感染
Jinnan Chen,Hong Lu
The Lancet Infectious Diseases Vol 26(1):p9
8
The smallest faith
最渺小的信念
Steven A Pergam
The Lancet Infectious Diseases Vol 26(1):p11
9
Negative results in long COVID clinical trials: choosing outcome measures for a heterogeneous disease
新冠肺炎长期症状临床试验的阴性结果：为异质性疾病选择预后指标
Lara Goxhaj,Lisa McCorkell,Femke van Rhijn-Brouwer,Letícia Soares,Julia Moore Vogel,Chloé de Canson
The Lancet Infectious Diseases Vol 26(1):p13
10
Strengthening global preparedness and response to arboviral disease threats: a call to action
加强全球应对虫媒病毒疾病威胁的准备和响应：行动呼吁
WHO Global Arbovirus Initiative Technical Advisory Group
世界卫生组织全球虫媒病毒倡议技术咨询小组
The Lancet Infectious Diseases Vol 26(1):p15
11
Introducing our cover artist for 2026: Daria Lada
介绍我们2026年的封面艺术家：达里亚·拉达
Marco De Ambrogi
The Lancet Infectious Diseases Vol 26(1):p17
Correspondence（读者来信）
12
Epidemiological and virological update on the emerging SARS-CoV-2 variant BA.3.2
新兴新冠病毒变异株BA.3.2的流行病学和病毒学最新情况
Lu Zhang,Nianzhen Chen,Amy Eichmann,Inga Nehlmeier,Anna-Sophie Moldenhauer,Metodi V Stankov,Christine Happle,Alexandra Dopfer-Jablonka,Georg M N Behrens,Markus Hoffmann,Stefan Pöhlmann
The Lancet Infectious Diseases Vol 26(1):e1
13
Effects of LP.8.1-adapted mRNA vaccination on SARS-CoV-2 variant neutralisation
Christine Happle,Markus Hoffmann,Metodi V Stankov,Inga Nehlmeier,Amy Eichmann,Torsten LP.8.1适应性mRNA疫苗接种对新冠病毒变异株中和作用的影响
Witte,Luis Manthey,Stefan Pöhlmann,Alexandra Dopfer-Jablonka,Georg M N Behrens
The Lancet Infectious Diseases Vol 26(1):e3
14
Artificial intelligence and spillover prediction: aligning innovation with empirical reality in One Health surveillance
人工智能与溢出预测：在“同一健康”监测中使创新与经验现实保持一致
Nader Ebrahimi,Amir Ghaemi
The Lancet Infectious Diseases Vol 26(1):e6
15
Artificial intelligence and spillover prediction: aligning innovation with empirical reality in One Health surveillance – Authors' reply
人工智能与溢出预测：在“同一健康”监测中使创新与经验现实保持一致——作者回复
Frank Aarestrup,Marion Koopmans
The Lancet Infectious Diseases Vol 26(1):e7
16
Time to tackle vaccine–HLA associations with artificial intelligence
是时候用人工智能解决疫苗-人类白细胞抗原关联问题了
Alexander J Mentzer,George Davey Smith,Teresa Lambe,Julian C Knight,Mary Carrington
The Lancet Infectious Diseases Vol 26(1):e8
Corrections（更正）
17
Correction to Lancet Infect Dis 2025; published online Oct 29.
《柳叶刀-传染病》2025年更正；在线发表于10月29日
https://doi.org/10.1016/S1473-3099(25)00466-9
The Lancet Infectious Diseases Vol 26(1):e9
18
Correction to Lancet Infect Dis 2025; published online Oct 27.
《柳叶刀-传染病》2025年更正；在线发表于10月27日
https://doi.org/10.1016/S1473-3099(25)00546-8
The Lancet Infectious Diseases Vol 26(1):e9
19
Correction to Lancet Infect Dis 2025; 25: 1084–96
《柳叶刀-传染病》2025年更正；25卷：1084-1096页
The Lancet Infectious Diseases Vol 26(1):e9
20
Correction to Lancet Infect Dis 2025; published online Nov 10.
《柳叶刀-传染病》2025年更正；在线发表于11月10日
https://doi.org/10.1016/S1473-3099(25)00550-X
The Lancet Infectious Diseases Vol 26(1):e9
Newsdesk（新闻台）
21
Highlights of IDWeek 2025
2025年IDWeek亮点
Phoebe Hall
The Lancet Infectious Diseases Vol 26(1):e10
22
WHO publishes update on global antibiotic resistance
世界卫生组织发布全球抗生素耐药性最新情况
Timothy Jesudason
The Lancet Infectious Diseases Vol 26(1):e11
23
European Commission to fund new medicines for dengue
欧盟委员会资助登革热新药研发
Sanjeet Bagcchi
The Lancet Infectious Diseases Vol 26(1):e12
24
Second report from the UK Covid-19 Inquiry
英国新冠肺炎调查第二次报告
Talha Burki
The Lancet Infectious Diseases Vol 26(1):e13
25
Infectious disease surveillance update
传染病监测最新情况
Cahal McQuillan
The Lancet Infectious Diseases Vol 26(1):e14
26
Research in brief
研究简讯
Priya Venkatesan
The Lancet Infectious Diseases Vol 26(1):e15
Obituary（讣告）
27
Jean Louis Abdourahim Ndiaye
让·路易斯·阿卜杜拉希姆·恩迪亚耶
Sanjeet Bagcchi
The Lancet Infectious Diseases Vol 26(1):p19
Profile（人物介绍）
28
Fortunate Machingura—tackling climate change and disease
福图纳特·马辛古拉——应对气候变化与疾病
Tony Kirby
The Lancet Infectious Diseases Vol 26(1):p20
Media Watch（媒体观察）
Book（书籍）
29
The social and political drivers behind pandemics
大流行背后的社会和政治驱动因素
Emma Louise Fabiani
The Lancet Infectious Diseases Vol 26(1):p21
Articles（论著）
30
Dynamics of endemic virus re-emergence in children in the USA following the COVID-19 pandemic (2022–23): a prospective, multicentre, longitudinal, immunoepidemiological surveillance study
新冠肺炎疫情后美国儿童地方性病毒重新出现的动态（2022-23年）：一项前瞻性、多中心、纵向、免疫流行病学监测研究
Hai Nguyen-Tran,Sang Woo Park,Matthew R Vogt,Perdita Permaul,Alicen B Spaulding,Michelle L Hernandez,Jennifer A Bohl,Sucheta Godbole,Tracy J Ruckwardt,Peter W Krug,Daniel L Moss,Alexandrine Derrien-Colemyn,Ananda Chowdhury,Gabrielle Dziubla,Lu Wang,Mike Castro,Sandeep R Narpala,Elizabeth R Longtine,Amy R Henry,Teri-T B Ngo,Leonid Dzantiev,George B Sigal,C Jessica Metcalf,David W Kimberlin,Samuel R Dominguez,Abraham Mittelman,Adrian B McDermott,Leonid A Serebryannyy,Bryan Grenfell,Kevin Messacar,Daniel C Douek
The Lancet Infectious Diseases Vol 26(1):p22
31
Sotrovimab versus usual care in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
索托维单抗与常规治疗对住院新冠肺炎患者的疗效对比（RECOVERY）：一项随机、对照、开放标签、平台试验
RECOVERY Collaborative Group
RECOVERY协作组
The Lancet Infectious Diseases Vol 26(1):p34
32
A 3-month clofazimine–rifapentine-containing regimen for drug-susceptible tuberculosis versus standard of care (Clo-Fast): a randomised, open-label, phase 2c clinical trial
含氯法齐明-利福喷丁的3个月方案与标准治疗方案治疗药物敏感性结核病的对比（Clo-Fast）：一项随机、开放标签、2c期临床试验
John Z Metcalfe,Isabelle R Weir,Kimberly K Scarsi,Alberto Mendoza-Ticona,Samuel Pierre,Luke Hall,Jorge Leon-Cruz,Elin M Svensson,Simon E Koele,Wadzanai Samaneka,Cecilia Kanyama,Maxwell Yohane,Neetal Nevrekar,Busisiwe Ntsalaze,Jean Bernard Marc,Melanie Goth,Gary Maartens,Richard Chaissonon behalf of the ACTG A5362 study team
The Lancet Infectious Diseases Vol 26(1):p46
33
Global policy responses to antimicrobial resistance, 2021–22: a systematic governance analysis of 161 countries and territories
2021-22年全球应对抗菌药物耐药性的政策反应：对161个国家和地区进行的系统性治理分析
Jay Patel,Sahar Saeedi Moghaddam,Sruthi Ranganathan,Neil Vezeau,Emily O'Neill,Anne Harant,Michael Stolpe,Lothar H Wieler,Tim Eckmanns,Devi Sridhar
The Lancet Infectious Diseases Vol 26(1):p55
34
Efficacies of artemether–lumefantrine, artesunate–amodiaquine, dihydroartemisinin–piperaquine, and artesunate–pyronaridine for the treatment of uncomplicated Plasmodium falciparum malaria in children aged 6 months to 10 years in Uganda: a randomised, open-label, phase 4 clinical trial
乌干达6个月至10岁儿童使用蒿甲醚-本芴醇、青蒿琥酯-阿莫地喹、双氢青蒿素-哌喹和青蒿琥酯-吡喃隆治疗无并发症恶性疟原虫疟疾的疗效：一项随机、开放标签、4期临床试验
Moses R Kamya,Joaniter I Nankabirwa,Chris Ebong,Victor Asua,Moses Kiggundu,Stephen Orena,Martin Okitwi,Stephen Tukwasibwe,Bosco Agaba,Daniel Kyabayinze,Jimmy Opigo,Damian Rutazana,Benjamin Binagwa,Edward Mugwanya,Shakira Babirye,Gloria Sebikaari,Patrick M Condo,Grace Appiah,Sam L Nsobya,Melissa D Conrad,Philip J Rosenthal,Leah F Moriarty,Adoke Yeka
The Lancet Infectious Diseases Vol 26(1):p67
35
Safety, tolerability, and protective efficacy of a radiation-attenuated, whole sporozoite malaria vaccine in children in Gabon: a randomised, double-blind, placebo-controlled, phase 2 trial
加蓬儿童使用辐射减毒全孢子虫疟疾疫苗的安全性、耐受性和保护效力：一项随机、双盲、安慰剂对照、2期试验
Selidji T Agnandji,Jeroen Bok,Ayodele Alabi,Anita L Kabwende,Armel Mbouna,Juste Bie,Eleonne Moukiti,Albert Lalremruata,Meral Esen,Andrea Kreidenweiss,Natasha KC,B Kim Lee Sim,Thomas L Richie,L W Preston Church,Matthew B B McCall,Stephen L Hoffman,Peter G Kremsner,Benjamin Mordmüller
The Lancet Infectious Diseases Vol 26(1):p79
36
Effectiveness of the TAK-003 dengue vaccine in adolescents during the 2024 outbreak in São Paulo, Brazil: a test-negative, case–control study
TAK-003登革热疫苗在2024年圣保罗暴发期间对青少年的有效性：一项测试阴性病例对照研究
Otavio T Ranzani,Felippe Lazar Neto,Lisany Krug Mareto,Thiago Sanches Brumatti,Roberto Dias de Oliveira,Patricia Vieira da Silva,Edinéia Ribeiro dos Santos,Tatiana Lang D' Agostini,Regiane A Cardoso De Paula,Natalie E Dean,Albert I Ko,Derek A T Cummings,Jason R Andrews,Matt D T Hitchings,Julio Croda
The Lancet Infectious Diseases Vol 26(1):p91
37
Rifasutenizol-based triple therapy versus bismuth plus clarithromycin-based triple therapy for first-line treatment of Helicobacter pylori infection in China (EVEREST-HP): a phase 3, multicentre, randomised, triple-dummy, double-blind, controlled, non-inferiority trial
以利法苏替尼唑为基础的三联疗法与铋剂加克拉霉素为基础的三联疗法作为中国幽门螺杆菌感染一线治疗的对比（EVEREST-HP）：一项3期、多中心、随机、三模拟、双盲、对照、非劣效性试验
Zhiqiang Song,Liya Zhou,Weihong Wang,Cheng Lan,Tongyu Tang,Jun Xie,Huizhen Fan,Xuehong Wang,Xiuli Zuo,Yin Zhu,Chengxia Liu,Yongsong Gu,Huang Feng,Xiang Gao,Qing Zhang,Hong Zhang,Jing Chen,Guozhu Geng,Zhenkun Maon behalf of the EVEREST-HP Study Group
The Lancet Infectious Diseases Vol 26(1):p101
Series（专题研讨会）
38
Prevention and Management of Infections in People who are Immunocompromised
免疫功能低下人群感染的预防和治疗
Innovation in active and passive immunisation of people who are immunocompromised: a call to action
免疫功能低下人群主动和被动免疫接种的创新：行动呼吁
Joshua A Hill,Jim Boonyaratanakornkit,Malgorzata Mikulska,Benjamin W Teh,William O Hahn,Ghady Haidar,Catherine Liu,Deepali Kumar,Michael G Ison,Natasha Halasa
The Lancet Infectious Diseases Vol 26(1):e16
39
Prevention and Management of Infections in People who are Immunocompromised
免疫功能低下人群感染的预防和治疗
Tackling antimicrobial resistance in people who are immunocompromised: leveraging diagnostic and antimicrobial stewardship
应对免疫功能低下人群的抗菌药物耐药性：利用诊断和抗菌药物管理
Catherine Liu,Emily A Rosen,Erica J Stohs,Hannah Imlay,Masayuki Nigo,Lee S Gottesdiener,Miranda So,Frank Tverdek,Sanjeet Dadwal,Carlota Gudiol,Michael J Satlin,Susan K Seo,Jason A Trubiano,Ritu Banerjee,Kimberly E Hanson,Lilian M Abbo
The Lancet Infectious Diseases Vol 26(1):e30
Review（综述）
40
Unveiling the incidences and trends of alveolar echinococcosis in Europe: a systematic review from the KNOW-PATH project
揭示欧洲肺泡棘球蚴病的发病率和趋势：来自KNOW-PATH项目的系统综述
Adriano Casulli,Bernadette Abela,Daniele Petrone,Barbara Šoba,Balázs Dezsényi,Jacek Karamon,Laurence Millon,Urmas Saarma,Daniela Antolová,François Chappuis,Severin Gloor,Marcel Stoeckle,Beat Müllhaupt,Relja Beck,Heimo Lagler,Felix Lötsch,Herbert Auer,Marie-Pierre Hayette,Libuše Kolářová,Sniedze Laivacuma,Mindaugas Šarkūnas,Vitalijus Sokolovas,Audronė Marcinkutė,Karin Troell,Ansgar Deibel,Pikka Jokelainen,Małgorzata Sulima,Dagny Krankowska,Stillhard Roman,Gaëtan-Romain Joliat,Nermin Halkic,Solange Bresson-Hadni,Joanna Halina Bednarek,Andrzej Załęski,Małgorzata Paul,Sheraz Yaqub,Mogens Jensenius,Joke van der Giessen,Laura Nabarro,Peter Chiodini,Florent Demonmerot,Jenny Knapp,Beate Grüner,Peter Kern,Lynn Peters,Federica Santolamazza,Azzurra Santoro
The Lancet Infectious Diseases Vol 26(1):e49
Personal View（个人观点）
41
Azithromycin mass drug administration: balancing survival benefits and risks in children
阿奇霉素大规模药物给药：平衡儿童生存益处与风险
Nubwa Medugu,Ian C Michelow,Claudette Poole,Stephen K Obaro
The Lancet Infectious Diseases Vol 26(1):e62
Clinical Picture（临床影像）
42
Unexpected finding in a 17-year-old female undergoing screening colonoscopy
17岁女性接受筛查结肠镜检查时的意外发现
Ziheng Calvin Xu,Ethan Tan,Mayur Garg
The Lancet Infectious Diseases Vol 26(1):e75
THE LANCET Infectious Diseases. Volume 26Number 2
柳叶刀传染病学 26卷 2期
https://www.thelancet.com/journals/laninf/issue/current
EDITORIAL(社论)
1
Call for letters
征稿启事
The Lancet Infectious Diseases
The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：p111
Comment（述评）
2
Long COVID is here to stay—even in children
长期新冠症状将持续存在——即使在儿童中亦是如此
Danilo Buonsenso
The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：p112
3
Beyond ritonavir-boosted nirmatrelvir: the case for ensitrelvir in COVID-19 treatment
利托那韦强化版奈玛特韦之外的选择：恩赛特韦在新冠肺炎治疗中的应用
Ming Hong Choi,Ivan Fan Ngai Hung
The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：p113
4
A new monoclonal in the arMAMentarium against malaria
抗疟“武器库”中的新型单克隆抗体
Freia-Raphaella Lorenz,Matthew B B McCall
The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：p115
5
Household transmission of mpox in Africa: limited in adults but more prevalent in children
非洲猴痘家庭传播情况：在成人中传播有限，但在儿童中更为普遍
Oriol Mitjà,Michael Marks
The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：p117
6
The lasting lessons of mpox: infection, vaccination, and immune memory
猴痘带来的持久教训：感染、疫苗接种和免疫记忆
Raianna Fantin,Camila H Coelho
The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：p118
7
Xpert-Ultra for diagnosing asymptomatic tuberculosis
Xpert-Ultra用于诊断无症状结核病
Xia Yu,Hairong Huang
The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：p120
8
The genomic surveillance gap: averting the antimicrobial resistance pandemic requires global equity and action
基因组监测的差距：避免抗菌药物耐药性大流行需要全球公平与行动
David M Aanensen,Iruka N Okeke,Pilar Donado-Godoy,Beverly Egyir,Ravikumar K Lingegowda,Sonia Siaon behalf of the NIHR Global Health Research Unit on Genomic Surveillance of AMR
The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：p122
Correspondence（读者来信）
9
Spillover in dengue trials
登革热试验中的溢出效应
Thomas A Smith,Samuel I Watson
The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：e77
10
Spillover in dengue trials – Author's reply
登革热试验中的溢出效应——作者回复
Fernando Abad-Franch
The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：e78
11
Updating the traditional voriconazole trough concentration range
传统的伏立康唑谷浓度范围更新
Rongqiang Liao,Xiaoyuan Zheng
The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：e79
12
Updating the traditional voriconazole trough concentration range – Authors' reply
传统的伏立康唑谷浓度范围更新——作者回复
Inderpaul Singh Sehgal,Ritesh Agarwal,Valliappan Muthu
The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：e80
13
Clinical course and neurological profile of Kyasanur Forest disease
基萨努尔森林病的临床病程和神经特征
Nitin Gupta,Tirlangi Praveen Kumar
The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：e82
Corrections（更正）
14
Correction to Lancet Infect Dis 2025; published online Oct 10. https://doi.org/10.1016/S1473-3099(25)00482-7
对《柳叶刀-传染病》2025年发表内容的更正；10月10日在线发表。https://doi.org/10.1016/S1473-3099(25)00482-7
The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：e83
15
Correction to Lancet Infect Dis 2025; published online Dec 1. https://doi.org/10.1016/S1473-3099(25)00681-4
对《柳叶刀-传染病》2025年发表内容的更正；12月1日在线发表。https://doi.org/10.1016/S1473-3099(25)00681-4
The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：e83
Newsdesk（新闻台）
16
Promising early data for sorfequiline
索氟维林早期数据令人鼓舞
Ed Holt
The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：e84
17
Highlights from ASTMH 2025
2025年美国热带医学与卫生学会年会亮点
Marco De Ambrogi
The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：e85
18
Brazil approves domestic single-shot dengue vaccine
巴西批准国产单剂登革热疫苗
Marcia Triunfol
The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：e86
19
CDC cuts to childhood vaccine recommendations
美国疾控中心削减儿童疫苗接种建议
Priya Venkatesan
The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：e87
20
WHO launches unified plan for coronaviruses
世界卫生组织启动冠状病毒统一计划
Talha Burki
The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：e88
21
Infectious disease surveillance update
传染病监测更新
Cahal McQuillan
The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：e89
22
Research in brief
研究简讯
Priya Venkatesan
The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：e90
Obituary（讣告）
23
Walter Dowdle
沃尔特·道德尔
Sanjeet Bagcchi
The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：p124
Profile（人物简介）
24
Katie Anders—improving global dengue control
凯蒂·安德斯——改善全球登革热防控
Tony Kirby
The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：p125
Media Watch（媒体观察）
Film（电影）
25
Eliminating Guinea worm
根除麦地那龙线虫
Sanjeet Bagcchi
The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：p126
Articles（论著）
26
Long COVID associated with SARS-CoV-2 reinfection among children and adolescents in the omicron era (RECOVER-EHR): a retrospective cohort study
奥密克戎时代儿童与青少年长期新冠症状与SARS-CoV-2再感染的关联（RECOVER-EHR）：一项回顾性队列研究
Bingyu Zhang,Qiong Wu,Ravi Jhaveri,Ting Zhou,Michael J Becich,Yuriy Bisyuk,Frank Blanceró,Elizabeth A Chrischilles,Cynthia H Chuang,Lindsay G Cowell,Daniel Fort,Carol R Horowitz,Susan Kim,Nathalia Ladino,David M Liebovitz,Mei Liu,Abu S M Mosa,Hayden T Schwenk,Srinivasan Suresh,Bradley W Taylor,David A Williams,Jeffrey S Morris,Christopher B Forrest,Yong Chenon behalf of the RECOVER Consortium
The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：p127
27
Antiviral efficacy of oral ensitrelvir versus oral ritonavir-boosted nirmatrelvir in COVID-19 (PLATCOV): an open-label, phase 2, randomised, controlled, adaptive trial
口服恩赛特韦与口服利托那韦强化版奈玛特韦在新冠肺炎治疗中的抗病毒疗效（PLATCOV）：一项开放标签、2期、随机、对照、适应性试验
William H K Schilling,Podjanee Jittamala,Phrutsamon Wongnak,James A Watson,Simon Boyd,Viravarn Luvira,Tanaya Siripoon,Thundon Ngamprasertchai,Elizabeth M Batty,Ellen Beer,Shivani Singh,Tanatchakorn Asawasriworanan,Timothy Seers,Koukeo Phommasone,Terry John Evans,Varaporn Kruabkontho,Thatsanun Ngernseng,Jaruwan Tubprasert,Mohammad Yazid Abdad,Wanassanan Madmanee,Jindarat Kouhathong,Kanokon Suwannasin,Watcharee Pagornrat,Tianrat Piteekan,Borimas Hanboonkunupakarn,Kittiyod Poovorawan,Manus Potaporn,Attasit Srisubat,Bootsakorn Loharjun,Kesinee Chotivanich,Mallika Imwong,Sasithon Pukrittayakamee,Arjen M Dondorp,Nicholas P J Day,Watcharapong Piyaphanee,Weerapong Phumratanaprapin,Nicholas J Whiteon behalf of the PLATCOV Collaborative Group
The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：p139
28
Cefiderocol versus standard therapy for hospital-acquired and health-care-associated Gram-negative bacterial bloodstream infection (the GAME CHANGER trial): an open-label, parallel-group, randomised trial
头孢地尔与标准疗法治疗医院获得性和医疗保健相关性革兰氏阴性菌血流感染（GAME CHANGER试验）：一项开放标签、平行分组、随机试验
David L Paterson,Helmi Sulaiman,Po-Yu Liu,Mark D Chatfield,Mesut Yilmaz,Zeti Norfidiyati Salmuna,Mohd Zulfakar Mazlan,Siriluck Anunnatsiri,Rujipas Sirijatuphat,Darunee Chotiprasitsakul,David C Lye,Jyoti Somani,Shirin Kalimuddin,Abdullah T Aslan,Visanu Thamlikitkul,Yi-Tzu Lee,Ya-Sung Yang,Yi-Tsung Lin,Wan Nurliyana Wan Ramli,Chien-Hao Tseng,Sophia Archuleta,Yvonne Fu Zi Chan,Brian M Forde,Hugh Wright,Adam G Stewart,Kay A Ramsay,Weiping Ling,Vicki Rossi,Tiffany M Harris-Brown,Patrick N A Harrison behalf of the GAME CHANGER Trial Investigators
The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：p148
29
Efficacy and safety of ascending doses of orodispersible ivermectin co-administered with albendazole for Trichuris trichiura infections in preschool-aged children in Tanzania: a 坦桑尼亚学龄前儿童感染毛首鞭形线虫时，递增剂量口服分散片伊维菌素与阿苯达唑联合用药的疗效和安全性：一项单盲、随机、对照、剂量递增、2期试验
single-blind, randomised, controlled, dose-ranging, phase 2 trial
Viviane P Sprecher,Annina Schnoz,Stefan Biendl,Halima S Hussein,Sarah O Najim,Mohammed N Ali,Ibrahim S Mohammed,Said M Ali,Jan Hattendorf,Jennifer Keiser
The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：p160
30
Human monoclonal antibody MAM01 for protection against malaria in adults in the USA: a first-in-human, phase 1, dose-escalation, double-blind, placebo-controlled, adaptive trial
人源单克隆抗体MAM01保护美国成年人免受疟疾侵害：一项首次人体、1期、剂量递增、双盲、安慰剂对照、适应性试验
Kirsten E Lyke,Andrea A Berry,Matthew B Laurens,Jennifer Winkler,Sudhaunshu Joshi,Abra Rachida Koudjra,Lauryn Butler,Peter F Billingsley,Tales Pascini,Asha Patil,B Kim Lee Sim,Grace Fitzgerald,Julie Riegel,Kayla Andrews,Micha Levi,Aparna B Anderson,Charles D Wells,Hong Liu,James Huleatt,R Scott Miller
The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：p170
31
Characterising household transmission dynamics of clade Ib mpox in Burundi: a prospective cohort study
布隆迪Ib分支猴痘家庭传播动力学特征：一项前瞻性队列研究
Raoul Kamadjeu,Ferdinand Nsengimana,Manassé Nimpagaritse,Edna Moturi,Eric Kezakarayagwa,Rose Nkiko,Jonas Ngendakumana,Rémy Nimubona,Liliane Nkengurutse,Hamady Ba,Dionis Nizigiyimana,Paul Ngwakum,Mame Selbee Diouf,France Bégin,Joseph Nyandwi,Douglas James Noble
The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：p182
32
Long-term consequences of monkeypox virus infection or modified vaccinia virus Ankara vaccination in Belgium (MPX-COHORT and POQS-FU-PLUS): a 24-month prospective and retrospective cohort study
比利时猴痘病毒感染或改良痘苗病毒安卡拉株疫苗接种的长期后果（MPX-COHORT和POQS-FU-PLUS）：一项为期24个月的前瞻性和回顾性队列研究
Christophe Van Dijck,Nicole Berens-Riha,Luca M Zaeck,Cécile Kremer,Jacob Verschueren,Jasmine Coppens,Fien Vanroye,Elisabeth Willems,Evi Bosman,Natalie De Cock,Bart Smekens,Leen Vandenhove,Odin Goovaerts,Anke Van Hul,Janne Wouters,Bart K M Jacobs,Stefanie Bracke,Matilde Hens,Isabel Brosius,Elise De Vos,Eugene Bangwen,Sarah Houben,Achilleas Tsoumanis,Pedro Henrique Lopes Ferreira Dantas,Jojanneke Rutgers,Amber Lipman,Koen Wijnans,Patrick Soentjens,Emmanuel Bottieau,Chris Kenyon,Johan van Griensven,Thijs Reyniers,Niels Horst,Kevin K Ariën,Marjan Van Esbroeck,Andrea Torneri,Koen Vercauteren,Wim Adriaensen,Rory D de Vries,Joachim Mariën,Laurens Liesenborghs
The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：p190
33
Long-term risk of tuberculosis among individuals with Xpert Ultra trace screening results in Uganda: a longitudinal follow-up study
乌干达Xpert Ultra微量筛查结果阳性个体患结核病的长期风险：一项纵向随访研究
Joowhan Sung,Mariam Nantale,Annet Nalutaaya,Patrick Biché,James Mukiibi,Joab Akampurira,Rogers Kiyonga,Francis Kayondo,Michael Mukiibi,Caitlin Visek,Caleb E Kamoga,David W Dowdy,Achilles Katamba,Emily A Kendall
The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：p203
Review（综述）
34
Invasive group A streptococcal infections: lessons learned from the 2022–23 upsurge
侵袭性A组链球菌感染：从2022-23年激增中吸取的教训
Alix Flamant,Alicia Demirjian,Theresa Lamagni,Julie Toubiana,Pierre R Smeesters,Jérémie F Cohen
The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：e91
35
A clinical practice guideline for tuberculous meningitis
结核性脑膜炎临床实践指南
Joseph Donovan,Fiona V Cresswell,Elizabeth W Tucker,Angharad G Davis,Ursula K Rohlwink,Julie Huynh,Regan Solomons,James A Seddon,Nathan C Bahr,Arjan van Laarhoven,Suzanne T Anderson,Sanjay K Jain,Felicia C Chow,Sophie Pattison,James E Scriven,Gabriela Singh,Rob E Aarnoutse,Jan-Willem C Alffenaar,Sofiati Dian,Abi Manesh,Robin Basu Roy,Varinder Singh,Ronald van Toorn,Caryn M Upton,Reinout van Crevel,Kelly E Dooley,Diana Gibb,David Meya,Robert J Wilkinson,Ewelina Rogozińska,Usha K Misra,Anthony Figaji,Guy E Thwaites
The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：e96
36
Towards shorter therapy for candidaemia: defining uncomplicated candidaemia in adults
缩短念珠菌血症疗程：界定成人非复杂性念珠菌血症
Ilana Reinhold,Susanne Picardi,Blasius Liss,Danila Seidel,Jannik Stemler,Philipp Koehler,Tamara Ruegamer,Rosanne Sprute,Oliver A Cornely
The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：e112
Personal View（个人观点）
37
A transformation in cholera surveillance
霍乱监测的变革
Amanda K Debes,Erin T Baumgartner,Kendra N Williams,David A Sack
The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：e124
Clinical Picture（临床图像）
38
Paediatric ocular toxocariasis with relentless progression despite negative metagenomic testing
尽管宏基因组检测呈阴性，但儿科眼弓蛔虫病仍持续进展
Diya Shah,Shiama Balendra,Harry Petrushkin,Anamika Patel
The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：e130
THE LANCET Infectious Diseases. Volume 26Number 3
柳叶刀传染病学 26卷 3期
https://www.thelancet.com/journals/laninf/issue/current
EDITORIAL（社论）
1
Promises and challenges of AI in infectious diseases
人工智能在传染病领域的承诺与挑战
The Lancet Infectious Diseases
The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：p213
COMMENT（述评）
2
More real-world evidence for RSV vaccines in the global community
全球范围社区呼吸道合胞病毒（RSV）疫苗的更广泛的现实证据
Kristina L Bajema,Wesley H Self
The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：p214
3
Rapid diagnostic antigen tests for mpox and the need for decentralised testing—not quite there yet
猴痘快速诊断抗原检测及分散检测的必要性——尚待完善
Daniel Mukadi-Bamuleka,Kevin K Ariën
The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：p215
4
Solving the data bottleneck for artificial intelligence in infectious diseases
解决传染病人工智能领域的数据瓶颈问题
Cesar de la Fuente-Nunez
The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：p217
5
Artificial intelligence and One Health: potential for spillover prediction?
人工智能与“同一健康”理念：能否预测病原体外溢？
Marion Koopmans,Istvan Csabai,Daniel Remondini,Emma Snary,Frank Aarestrup
The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：p219
6
Artificial intelligence in the development of vaccines for infectious diseases
人工智能在传染病疫苗研发中的应用
Steve Black,Shabir A Madhi,Rino Rappuoli
The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：p221
7
Peer review at The Lancet Infectious Diseases in 2025
2025年《柳叶刀-传染病学》期刊专家评审
Ursula Hofer
The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：p223
8
Thank you to The Lancet Infectious Diseases statistical and peer reviewers in 2025
感谢2025年《柳叶刀-传染病学》期刊的统计学及评审专家
The Lancet Infectious Diseases Editors
The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：e132
CORRESPONDENCE（读者来信）
9
Methodological considerations in the attribution of long COVID to first or second infection
首次或二次感染导致长期新冠症状的方法学考量
Sara Carazo,Danuta M Skowronski,Manale Ouakki,Gaston De Serres
The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：e139
10
Methodological considerations in the attribution of long COVID to first or second infection – Authors' reply
首次或二次感染导致长期新冠症状的方法学考量——作者回复
Bingyu Zhang,Qiong Wu,Ravi Jhaveri,Christopher B Forrest,Yong Chen
The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：e141
11
Humoral immunity after LP.8.1 monovalent vaccines against a broad range of SARS-CoV-2 variants including XEC, LP.8.1, NB.1.8.1, XFG, and BA.3.2
LP.8.1单价疫苗针对包括XEC、LP.8.1、NB.1.8.1、XFG和BA.3.2在内的多种SARS-CoV-2变异株的体液免疫应答
Yu Kaku,Mizuka Fujiwara,Keiya Uriu,Maximilian Stanley Yo,Shusuke Kawakubo,Jumpei Ito,Naoya Itoh,Yoshifumi Uwamino,Fumitake Saito,Hironori Satoh,The Genotype to Phenotype Japan (G2P-Japan) Consortium,Kei Sato
The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：e142
12
Precision diagnostics for MBLs: the true game changer in treating antimicrobial resistance
金属β-内酰胺酶精准诊断：治疗抗菌药物耐药性的真正变革者
Brenda A Warecki,María F Mojica,Alejandro J Vila,Robert A Bonomo
The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：e144
13
Precision diagnostics for MBLs: the true game changer in treating antimicrobial resistance – Authors' reply
金属β-内酰胺酶精准诊断：治疗抗菌药物耐药性的真正变革者——作者回复
David L Paterson,Abdullah T Aslan,Patrick N A Harris
The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：e145
CORRECTIONS（更正）
14
Correction to Lancet Infect Dis 2025; published online Dec 9. https://doi.org/10.1016/S1473-3099(25)00659-0
《柳叶刀-传染病学》2025年发表文章勘误；在线发表于12月9日。https://doi.org/10.1016/S1473-3099(25)00659-0
The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：e146
15
Correction to Lancet Infectious Diseases 2026; published online Jan 20. https://doi.org/10.1016/S1473-3099(25)00773-X
《柳叶刀-传染病学》2026年发表文章勘误；在线发表于1月20日。https://doi.org/10.1016/S1473-3099(25)00773-X
The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：e146
NEWSDESK（新闻台）
16
Rabies an increasing threat in Ukraine
乌克兰狂犬病威胁日益加剧
Ed Holt
The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：e147
17
People needing trachoma interventions at record low
需要沙眼干预措施的人数创历史新低
Timothy Jesudason
The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：e148
18
Uneven STI response in EU/EEA countries
欧盟/欧洲经济区国家性传播感染应对措施不均衡
Sanjeet Bagcchi
The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：e149
19
Controversial HBV vaccine trial in Guinea-Bissau halted
几内亚比绍有争议的乙型肝炎病毒疫苗试验被叫停
Talha Burki
The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：e150
20
Research in brief
研究简讯
Priya Venkatesan
The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：e151
OBITUARY（讣告）
21
Ivan Hirsch
伊万·赫希
Sanjeet Bagcchi
The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：p224
PROFILE（人物介绍）
22
Reem Abu Shomar— championing water safety in Gaza
里姆·阿布·舒马尔——加沙地带水安全倡导者
Tony Kirby
The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：p225
MEDIA WATCH（媒体观察）
Book（书籍）
23
A prescription for public health literacy
提升公众健康素养的良方
Vijay Shankar Balakrishnan
The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：p226
Book（书籍）
24
Imagining the inevitable
想象不可避免之事
Cahal McQuillan
The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：p227
Film（电影）
25
Women's autonomy, safe sex and HIV prevention
女性自主权、安全性行为与艾滋病预防
Sanjeet Bagcchi
The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：p228
ARTICLES（论著）
26
Vaccine effectiveness of a bivalent respiratory syncytial virus (RSV) pre-F vaccine against RSV-associated hospital admission among adults aged 75–79 years in England: a multicentre, test-negative, case–control study
英国75-79岁成年人中双价呼吸道合胞病毒（RSV）预融合F蛋白疫苗对RSV相关住院的有效性：一项多中心、检测阴性、病例对照研究
Rebecca Symes,Heather J Whitaker,Shazaad Ahmad,David Arnold,Suryabrata Banerjee,Cariad M Evans,Robin Gore,Jennifer Hart,Katy Heaney,Onn Min Kon,Anne Melhuish,Munira Ortale Zogaib,Emanuela Pelosi,Najib M Rahman,Gerrit Woltmann,Tricia McKeever,Maria Zambon,Conall H Watson,Wei Shen Lim,Jamie Lopez Bernalon behalf of the HARISS network collaborators
The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：p229
27
Oral itraconazole versus oral voriconazole for treatment-naive patients with chronic pulmonary aspergillosis in India (VICTOR-CPA trial): a single-centre, open-label, randomised, controlled, superiority trial
印度治疗初治慢性肺曲霉病患者口服伊曲康唑与口服伏立康唑的对比研究（VICTOR-CPA试验）：一项单中心、开放标签、随机、对照、优效性试验
Inderpaul Singh Sehgal,Ritesh Agarwal,Sahajal Dhooria,Kuruswamy Thurai Prasad,Valliappan Muthu,Ashutosh Nath Aggarwal,Shivaprakash M Rudramurthy,Mandeep Garg,Arunaloke Chakrabarti
The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：p239
28
Accounting for non-adherence to assigned antibiotic treatment duration for bloodstream infection (BALANCE): a post-hoc analysis of a randomised clinical trial
血流感染抗生素治疗疗程依从性考量（BALANCE）：一项随机临床试验的事后分析
Sean W X Ong,Ruxandra Pinto,Robert K Mahar,Asgar Rishu,Joshua S Davis,Robert A Fowler,Steven Y C Tong,Nick Danemanfor the BALANCE trial consortium
The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：p250
29
Field evaluation of a rapid antigen test for mpox in the Democratic Republic of the Congo and Uganda: a multicentre, prospective, diagnostic accuracy study
刚果民主共和国和乌干达猴痘快速抗原检测的现场评估：一项多中心、前瞻性、诊断准确性研究
Barnabas Bakamutumaho,David Lupande Mwenebitu,Winters Muttamba,Ingrid Ampeire,Henry Kyobe Bosa,Esto Bahizire,Bertin Casinga Bisimwa,Andrew Obuku,Misaki Wayengera,Alison Sandeman,Matthew T G Holden,Patrick D M C Katoto,Bruce Kirenga,Deborah A Williamson,Wilber Sabiiti
The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：p260
30
Complications and mortality of typhoid fever: an updated global systematic review and meta-analysis
伤寒热的并发症与死亡率：一项更新的全球系统综述与荟萃分析
Shruti Murthy,Nienke N Hagedoorn,Suzanne Faigan,Meera D Rathan,Christian S Marchello,John A Crump
The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：p270
31
Global, regional, and national burden of Chagas disease, 1990–2023: a systematic analysis for the Global Burden of Disease Study 2023
1990-2023年全球、区域和国家层面查加斯病负担：2023年全球疾病负担研究的系统分析
GBD 2023 Chagas Disease and RAISE Study Collaborators
The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：p284
32
Safety, tolerability, and immunogenicity of the ChAdOx1 RVF vaccine against Rift Valley fever among healthy adults in Uganda: a single-centre, single-blind, randomised, placebo-controlled, dose-escalation, phase 1 trial
乌干达健康成年人中ChAdOx1裂谷热疫苗的安全性、耐受性和免疫原性：一项单中心、单盲、随机、安慰剂对照、剂量递增的1期试验
Zacchaeus Anywaine,Jennifer Serwanga,Abu-Baker Mustapher Ggayi,Andrew Max Abaasa,Daniel Wright,Ben Gombe,Peter Ejou,Tamara Namata,Antony Kigozi,Naboth Tukamwesiga,Vincent Basajja,Violet Ankunda,Dora Jocelyn Mulondo,Florence Nambaziira,Ayoub Kakande,Wilson Kakeeto,Phiona Nabaggala,Daniel Jenkin,Alison Lawrie,Pedro Folegatti,Nguyen Tran,Christian Hansen,Alison M Elliott,Adrian V S Hill,George M Warimwe,Pontiano Kaleebu
The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：p302
33
Immunogenicity and safety of an 18-month booster dose of the VLA15 Lyme borreliosis vaccine candidate after primary immunisation in children, adolescents, and adults in the USA: a randomised, observer-blind, placebo-controlled, phase 2 trial
美国儿童、青少年和成人基础免疫后18个月VLA15莱姆病疫苗候选物的加强免疫接种的免疫原性和安全性：一项随机、观察者盲法、安慰剂对照的2期试验
Laura Wagner,Michaela Obersriebnig,Romana Hochreiter,Vera Kadlecek,Julian Larcher-Senn,Lisa Hegele,Jason D Maguire,Timothy Murphy,Ulla Derhaschnig,Nicole Bézay,Juan Carlos Jaramillo,Susanne Eder-Lingelbach,Marc Messier
The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：p314
SERIES（研讨会）
Artificial Intelligence and Infectious Diseases
人工智能与传染病
34
Artificial intelligence and infectious diseases: an evidence-driven conceptual framework for research, public health, and clinical practice
人工智能与传染病：基于证据的研究、公共卫生和临床实践概念框架
Anna Odone,Chiara Barbati,Silvia Amadasi,Tanja Schultz,David B Resnik
The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：e152
35
Artificial intelligence and infectious disease diagnostics: state of the art and future perspectives
人工智能与传染病诊断：现状与未来展望
Luca Miglietta,Timothy M Rawson,Ronald Galiwango,Alex Tasker,Damien K Ming,Darlington Akogo,Cecilia Ferreyra,Eric O Aboagye,N Claire Gordon,Carolina Garcia-Vidal,Jesus Rodriguez-Manzano,Alison H Holmes
The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：e168
36
Artificial intelligence and infectious diseases: tackling antimicrobial resistance, from personalised care to antibiotic discovery
人工智能与传染病：应对抗菌药物耐药性，从个性化治疗到抗生素发现
Alex Howard,Nada Reza,Peter L Green,Mo Yin,Erin Duffy,Henry C Mwandumba,Alessandro Gerada,William Hope
The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：e181
REVIEW（综述）
37
Community-acquired respiratory virus infections in patients with haematological malignancies or undergoing haematopoietic cell transplantation: updated recommendations from the 10th European Conference on Infections in Leukaemia
血液系统恶性肿瘤患者或接受造血细胞移植患者社区获得性呼吸道病毒感染：第10届欧洲白血病感染会议更新建议
Marie von Lilienfeld-Toal,Fareed Khawaja,Francesca Compagno,Christine Robin,José-Luis Piñana,Simone Cesaro,Hermann Einsele,Per Ljungman,David Navarro,Michael Boeckh,Roy F Chemaly,Hans H Hirsch
The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：e193
CLINICAL PICTURE（临床图像）
38
Mycoplasma hominis toe osteomyelitis: a rare and unusual bone infection
人型支原体足趾骨髓炎：一种罕见且不寻常的骨感染
Cheryl Keel,Pauleen McSherry,Rebecca Thombre,Sendurann Nadarajah,Rediat Tewolde,Owen B
Spiller,Baharak Afshar
The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：e207
疫苗信使RNA
100 项与 Sotrovimab 相关的药物交易
登录后查看更多信息
外链
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| - | Sotrovimab | - |
研发状态
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 新型冠状病毒感染 | 美国 | 2021-05-26 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
| 研究 | 分期 | 人群特征 | 评价人数 | 分组 | 结果 | 评价 | 发布日期 |
|---|
临床1期 | 20 | (Sotrovimab) | 鑰餘襯築衊膚鏇窪獵齋(鹹築網鏇願艱簾繭繭鹹) = 遞選餘網蓋鏇壓壓獵網 遞淵構構糧製簾鹹憲積 (壓鹹鏇衊築顧壓鬱鑰築, 18.59) 更多 | - | 2025-02-13 | ||
(Venipuncture) | 築築衊艱獵網顧鏇製網 = 鏇遞壓簾糧糧範鏇醖鹽 築製窪鬱觸壓獵獵餘觸 (糧壓壓觸壓醖鏇衊壓膚, 窪蓋淵願窪積艱觸遞淵 ~ 鹹衊鹹壓衊糧膚選繭遞) 更多 | ||||||
临床4期 | 217 | 簾鑰簾窪齋顧襯獵憲廠 = 鏇醖蓋夢鏇繭醖簾鹽簾 醖繭築願衊憲鏇醖襯糧 (艱衊網衊窪網餘網鏇憲, 鹹衊顧壓築餘築膚蓋網 ~ 網簾鹽蓋醖醖鏇壓糧築) 更多 | - | 2024-10-15 | |||
临床1期 | 316 | (Part C: Cohort 1-Sotrovimab) | 廠選醖顧製築築衊醖鹹 = 餘範構鏇窪淵築鑰餘選 淵膚範艱製繭糧鏇鑰艱 (醖鏇齋鑰顧憲膚艱膚網, 窪齋鏇夢獵獵鏇觸齋夢 ~ 簾積鹽鑰淵鏇夢鑰醖鏇) 更多 | - | 2024-09-19 | ||
(Part C: Cohort 2-Sotrovimab) | 構夢顧醖鬱醖願鹽簾淵(網糧窪願夢齋衊鬱壓範) = 艱繭鹽觸選窪鑰艱衊構 範網齋鏇獵構積鏇願範 (鑰襯構艱範繭範築壓鹹, 餘醖鑰廠築齋獵簾餘顧 ~ 構製鹹淵選憲窪窪壓範) 更多 | ||||||
临床2期 | 93 | 鏇襯膚夢餘範壓鏇築製 = 餘餘鹽鬱鬱鏇艱襯艱鹽 憲蓋網鹽衊選憲襯壓壓 (鬱積淵壓淵觸網鹽積鹽, 製觸獵淵廠蓋衊製鹽蓋 ~ 淵獵鏇鬱願醖構觸鏇選) 更多 | - | 2024-08-15 | |||
临床1期 | 48 | (Part 1: Sotrovimab 500 mg IV (Japanese)) | 襯廠夢艱積積憲範網製(窪衊積淵膚製鹽鏇淵鹽) = 獵獵網淵簾醖願遞壓顧 獵鏇鏇襯範積顧鬱醖膚 (淵醖鏇構顧範築醖獵餘, 18.5) 更多 | - | 2024-06-07 | ||
(Part 1: Sotrovimab 500 mg IV (Caucasian)) | 襯廠夢艱積積憲範網製(窪衊積淵膚製鹽鏇淵鹽) = 壓積衊醖廠艱網壓鬱夢 獵鏇鏇襯範積顧鬱醖膚 (淵醖鏇構顧範築醖獵餘, 13.8) 更多 | ||||||
临床2期 | 8 | (Cohort A: Sotrovimab Intravenous (IV) (6 to Less Than [<] 12 Years)) | 顧鏇獵糧鏇蓋遞簾艱鹽(製構選構顧觸窪夢糧製) = 衊醖鬱窪製顧網積繭遞 齋獵衊觸齋蓋鏇顧夢衊 (觸選選觸構鬱餘範膚憲, 27.6) 更多 | - | 2024-01-03 | ||
(Cohort A: Sotrovimab Intravenous (IV) (12 to Less Than [<] 18 Years)) | 顧鏇獵糧鏇蓋遞簾艱鹽(製構選構顧觸窪夢糧製) = 製顧鏇衊廠膚襯願壓網 齋獵衊觸齋蓋鏇顧夢衊 (觸選選觸構鬱餘範膚憲, 28.5) 更多 | ||||||
临床3期 | 367 | (VIR-7831 Plus SOC) | 遞壓鑰構鬱餘齋鹹積繭 = 簾觸糧構襯夢蓋襯衊淵 鏇糧齋獵夢廠顧獵鏇觸 (齋艱膚襯鏇醖艱窪鬱膚, 糧鑰窪製鹹餘壓艱選願 ~ 遞醖繭製齋繭衊膚蓋憲) 更多 | - | 2023-11-18 | ||
Placebo+Remdesivir (Placebo Plus SOC) | 遞壓鑰構鬱餘齋鹹積繭 = 願齋鑰廠繭窪餘願鹹壓 鏇糧齋獵夢廠顧獵鏇觸 (齋艱膚襯鏇醖艱窪鬱膚, 鹽構廠遞顧簾選壓齋鹽 ~ 壓蓋膚積鹽襯鹽願淵膚) 更多 | ||||||
临床2/3期 | 1,057 | 餘築觸遞蓋獵範鏇襯糧(膚鹹鏇鑰範選窪鬱鏇鏇) = 網艱觸齋鹽願鏇範獵積 夢願願夢鹽衊憲鬱艱憲 (選築範鬱憲鹽願鑰繭鏇 ) | 积极 | 2023-09-13 | |||
Placebo | 餘築觸遞蓋獵範鏇襯糧(膚鹹鏇鑰範選窪鬱鏇鏇) = 憲窪夢壓壓鹹築願簾淵 夢願願夢鹽衊憲鬱艱憲 (選築範鬱憲鹽願鑰繭鏇 ) | ||||||
临床4期 | 4,571 | (Lilly Bamlanivimab) | 鹹衊糧艱簾顧構範窪鹽(鬱蓋壓網夢廠鑰糧淵築) = 鏇憲構廠艱顧網蓋願獵 願鬱繭鹽鏇積壓構顧積 (構鹽獵醖齋鹹製餘壓製, 構遞鹹窪膚襯醖鏇鹽夢 ~ 顧鏇衊襯顧遞憲觸鑰齋) 更多 | - | 2023-06-15 | ||
(Regeneron Casirivimab + Imdevimab) | 鹹衊糧艱簾顧構範窪鹽(鬱蓋壓網夢廠鑰糧淵築) = 鹹糧壓觸糧鏇壓繭蓋醖 願鬱繭鹽鏇積壓構顧積 (構鹽獵醖齋鹹製餘壓製, 觸壓築遞構遞鹹鏇簾範 ~ 網壓夢鬱鏇構壓願遞糧) 更多 | ||||||
临床3期 | 1,065 | (Main Study: Sotrovimab 500 mg IV) | 醖製獵蓋齋壓襯鹹範膚 = 襯鑰壓鬱築顧餘淵膚願 顧鏇範鬱簾積壓觸觸築 (艱獵製鹽夢鏇蓋糧窪範, 夢製顧鏇製艱願窪繭鬱 ~ 鹹鑰範衊蓋蓋夢鬱築製) 更多 | - | 2023-05-26 | ||
(Main Study: Sotrovimab 500 mg IM) | 醖製獵蓋齋壓襯鹹範膚 = 艱繭網顧鏇遞廠壓繭鬱 顧鏇範鬱簾積壓觸觸築 (艱獵製鹽夢鏇蓋糧窪範, 繭齋糧網築醖選窪繭蓋 ~ 餘製願繭夢鹹醖觸顧糧) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
生物类似药
生物类似药在不同国家/地区的竞争态势。请注意临床1/2期并入临床2期，临床2/3期并入临床3期
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用